Board Structure | Governance | ESG | Samsung Biologics | The Leading Global CDMO with End-to-End Services

<!DOCTYPE html>     <html lang="en">  <head> <meta charset="utf-8"> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta http-equiv="Content-Type" content="text/xml; charset=utf-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <link rel="canonical" href="https://samsungbiologics.com/esg/governance/board-structure"> <link rel="alternate" hreflang="en" href="https://samsungbiologics.com/esg/governance/board-structure" /> <link rel="alternate" hreflang="ko" href="https://samsungbiologics.com/kr/esg/governance/board-structure" /> <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"> <meta name="author" content="Samsung Biologics"/> <meta name="pathUs" content="/esg/governance/board-structure"/> <meta name="pathKR" content="/kr/esg/governance/board-structure"/> <meta name="description" content="The board of directors is composed of seven members consisting of three directors and four independent directors. Independent directors have no ties to the company either through transactions or as a former employee or inside director." /> <meta name="twitter:description" content="The board of directors is composed of seven members consisting of three directors and four independent directors. Independent directors have no ties to the company either through transactions or as a former employee or inside director." /> <meta property="og:title" content="Board Structure | Governance | ESG | Samsung Biologics | The Leading Global CDMO with End-to-End Services" /> <meta property="og:description" content="The board of directors is composed of seven members consisting of three directors and four independent directors. Independent directors have no ties to the company either through transactions or as a former employee or inside director." />  <meta property="og:url" content="https://samsungbiologics.com/esg/governance/board-structure" /> <meta property="og:image" content="https://samsungbiologics.com/resources/front/common/logo_sbl.png" /> <meta property="og:type" content="website" /> <meta property="og:site_name" content="Board Structure | Governance | ESG" />  <meta property="og:url" content="/esg/governance/board-structure" /> <meta property="og:description" content="The board of directors is composed of seven members consisting of three directors and four independent directors. Independent directors have no ties to the company either through transactions or as a former employee or inside director." /> <meta property="og:title" content="Board Structure | Governance | ESG" /> <meta name="twitter:title" content="Samsung Biologics | The Leading Global CDMO with End-to-End Services" /> <meta property="og:locale" content="en_US" /> <meta property="og:locale:alternate" content="ko_KR" /> <meta name="twitter:card" content="summary" />  <meta property="twitter:url" content="https://samsungbiologics.com/esg/governance/board-structure" /> <meta property="twitter:image" content="https://samsungbiologics.com/resources/front/common/logo_sbl.png" />  <link rel="shortcut icon" href="/resources/front/common/samsungbio.ico" /> <title>Board Structure | Governance | ESG | Samsung Biologics | The Leading Global CDMO with End-to-End Services </title>  <link href="/resources/front/en/css/compile/common_en.min.css?version=250211" rel="stylesheet" /> <script src="/resources/front/en/js/jquery-3.4.1.min.js"></script>  <link id="link-swiper-css" rel="stylesheet" href="/resources/front/en/css/lib/swiper.min.css"> <script id="script-swiper-js" src="/resources/front/en/js/swiper.min.js"></script>      <script src="/resources/front/en/js/common.js?version=250211"></script>       <script type="text/javascript"> var _CTX = ""; var _DATEPICKER_FORMAT = "yy.mm.dd"; </script>  <script type="text/javascript"> _linkedin_partner_id = "1600545"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script> <script type="text/javascript"> if (getCookie("useCookie")){ (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); }else{ console.log("linkedin disableCookies"); } </script>   <meta name="ahrefs-site-verification" content="efff83a00be2c112d9dfb4bd68e26175ee1dd64842a884c012f697722a8a9414">  <meta name="google-site-verification" content="Cb1_nDozq8Rt0jA_soflsk9cNYUqs0KUiJ3i2sIpE4E" /> </head><body> <div class="skip"> <a href="#sub_menu">Skip GNB</a> <a href="#content">Skip Content</a> </div> <div id="wrap">  <div id="header"> <div class="pix-in">  <h1> <a href="#" id="mainRoot" class="logo">  </a> </h1> <div class="nav"> <ul> <li> <a href="/about/our-dna" data-href2=""><span>About Us</span></a> <div class="depth2Wrap"> <div class="depth2 depth2_1"> <ul> <li> <a href="/about/our-dna" data-href2=""><span>Company</span></a> <ul class="depth3"> <li class="noDepth"><a href="/about/our-dna" data-href2=""><span>Our DNA</span></a></li> <li class="noDepth"><a href="/about/samsungbiologics-way" data-href2=""><span>Samsung Biologics Way</span></a></li> <li class="noDepth"><a href="/about/fact-sheet" data-href2="/front/en/aboutUs/factSheet.do"><span>Fact Sheet</span></a></li> <li class="noDepth"><a href="/about/milestones" data-href2="/front/en/aboutUs/milestones.do"><span>Milestones</span></a></li> </ul> </li> </ul>  <ul> <li> <a href="/about/leadership/key-executives" data-href2="/front/en/aboutUs/leadership/keyExecutives.do"><span>Leadership</span></a> <ul class="depth3"> <li><a href="/about/leadership/key-executives" data-href2="/front/en/aboutUs/leadership/keyExecutives.do"><span>Key Executives</span></a></li> <li><a href="/about/leadership/ceo" data-href2="/front/en/aboutUs/leadership/ceo.do"><span>CEO Message</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/about/headquarters" data-href2="" ><span>Location</span></a> <ul class="depth3"> <li> <a href="/about/headquarters" data-href2="" ><span>Headquarters</span></a> <ul class="depth4"> <li><a href="/about/bio-campus1"><span>- Bio Campus I</span></a></li> <li><a href="/about/bio-campus2"><span>- Bio Campus II : Plant 5</span></a></li> </ul> </li> <li><a href="/about/sba" data-href2="/front/en/aboutUs/sba.do" ><span>Samsung Biologics America</span></a></li> </ul> </li> </ul> </div> </div> </li> <li> <a href="/services/biopharma-development" data-href="/services/cdo/overview"><span>Our Services</span></a> <div class="depth2Wrap"> <div class="depth2 depth2_2"> <ul> <li> <a href="/services/biopharma-development" data-href="/services/cdo/overview"><span>Development Services</span></a> <ul class="depth3"> <li class="mobile"><a href="/services/biopharma-development" data-href="/services/cdo/overview" data-href2="/contract-development-organization"><span>Overview</span></a></li> <li><a href="/services/cdo/discovery" data-href2="" data-href=""><span>Late Discovery</span></a></li> <li><a href="/services/cdo/cell-line-development" data-href2="/front/en/ourServices/cdo/cellLineDevelopment.do" ><span>Cell Line Development</span></a></li> <li><a href="/services/cdo/process-development" data-href2="/front/en/ourServices/cdo/processDevelopment.do" ><span>Process Development</span></a></li> <li><a href="/services/cdo/analytical-development" data-href2="" ><span>Analytical Development</span></a></li>  <li><a href="/services/cdo/manufacturing" data-href2="/front/en/ourServices/cdo/manufacturing.do" ><span>Non-GMP / CGMP Manufacturing</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/services/biopharma-manufacturing" data-href2="/services/cmo/overview" data-href="/contract-manufacturing-organization"><span>Manufacturing Services</span></a> <ul class="depth3"> <li class="mobile"><a href="/services/biopharma-manufacturing" data-href2="/services/cmo/overview" data-href="/contract-manufacturing-organization" ><span>Overview</span></a></li> <li>  <a href="/services/cmo/mammalian-cell-culture" ><span>Drug Substance</span></a>    </li> <li><a href="/services/cmo/drug-product" data-href2="/front/en/ourServices/cmo/drugProductService.do" ><span>Drug Product</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/services/biopharma-quality" data-href="/services/quality/overview"><span>Quality Services</span></a> <ul class="depth3"> <li class="mobile"><a href="/services/biopharma-quality" data-href="/services/quality/overview" ><span>Overview</span></a></li> <li><a href="/services/quality/quality-assurance" data-href2="/front/en/ourServices/quality/qualityAssurance.do" ><span>Quality Assurance</span></a></li> <li><a href="/services/quality/quality-control" data-href2="/front/en/ourServices/quality/qualityControl.do" ><span>Quality Control</span></a></li>  <li><a href="/services/quality/analytical-testing-services" data-href2="/front/en/ourServices/quality/analyticalTestingServices.do"><span>Analytical Testing Services</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/services/adc"><span>New Modalities</span></a> <ul class="depth3"> <li><a href="/services/adc"><span>Antibody-Drug Conjugates </span></a></li> <li><a href="/services/newmodalities/mRNA"><span>mRNA</span></a></li>  </ul> </li> </ul> </div> </div> </li> <li> <a href="/careers/value" data-href2="/front/en/careers/whatWeValue.do"><span>Careers</span></a> <div class="depth2Wrap"> <div class="depth2 depth2_3"> <ul> <li><a href="/careers/value" data-href2="/front/en/careers/whatWeValue.do" ><span>Our Values</span></a></li> </ul> <ul> <li> <a href="/careers/working-with-us/career-development" data-href2="/front/en/careers/workingWithUs/careerDevelopment.do"><span>Working With Us</span></a> <ul class="depth3"> <li><a href="/careers/working-with-us/career-development" data-href2="/front/en/careers/workingWithUs/careerDevelopment.do" ><span>Career Development</span></a></li> <li><a href="/careers/working-with-us/benefits" data-href2="/front/en/careers/workingWithUs/benefits.do" ><span>Benefits</span></a></li> <li><a href="/careers/working-with-us/diversity-inclusion" data-href2="/front/en/careers/workingWithUs/diversityInclusion.do" ><span>Diversity & Inclusion</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/careers/apply/how-to-apply" data-href2="/front/en/careers/howtoApply/howtoApply.do"><span>How to Apply</span></a> <ul class="depth3"> <li><a href="/careers/apply/how-to-apply" data-href2="/front/en/careers/howtoApply/howtoApply.do" ><span>Application Process</span></a></li> <li class="hidden"><a href="/careers/apply/overseas" data-href2="/front/en/careers/howtoApply/overseasExperienced.do" ><span>OverseasExperienced</span></a></li> <li class="hidden"><a href="/careers/apply/local" data-href2="/front/en/careers/howtoApply/localExperienced.do" ><span>LocalExperienced</span></a></li> <li class="hidden"><a href="/careers/apply/u-level" data-href2="/front/en/careers/howtoApply/newHiresULevel.do" ><span>NewHiresULevel</span></a></li> <li class="hidden"><a href="/careers/apply/c-level" data-href2="/front/en/careers/howtoApply/newHiresCLevel.do" ><span>NewHiresCLevel</span></a></li> <li class="hidden"><a href="/careers/apply/intern" data-href2="/front/en/careers/howtoApply/intern.do" ><span>Intern</span></a></li> <li><a href="/careers/apply/faqs" data-href2="/front/en/careers/howtoApply/faqs.do" ><span>FAQs</span></a></li> </ul> </li> </ul>  <ul> <li><a href="/careers/recruitment-support/step1" data-groupurl="/careers/recruitment-support/"><span>Job Information</span></a></li> </ul> </div> </div> </li> <li> <a href="/esg/our-commitment" data-href2="#"><span>Sustainability</span></a> <div class="depth2Wrap"> <div class="depth2 depth2_4"> <ul> <li> <a href="/esg/our-commitment" data-href2="#"><span>ESG Management</span></a> <ul class="depth3"> <li><a href="/esg/our-commitment" data-href2="#" data-href="#" ><span>Our Commitment</span></a></li> <li><a href="/esg/resources" data-href2="#" data-href="#" ><span>Resources</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/esg/environment/climate-actions" data-href2="#"><span>Environmental</span></a> <ul class="depth3"> <li><a href="/esg/environment/climate-actions" data-href2="#" data-href="#" ><span>Climate Actions</span></a></li> <li><a href="/esg/environment/she" data-href2="#" data-href="#" ><span>SHE Management</span></a></li> <li><a href="/esg/environment/environment" data-href2="#" data-href="#" ><span>Environment</span></a></li> <li><a href="/esg/environment/safety" data-href2="#" data-href="#" ><span>Safety</span></a></li> <li><a href="/esg/environment/health" data-href2="#" data-href="#" ><span>Health</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/esg/social/human-rights" data-href2="#"><span>Social</span></a> <ul class="depth3"> <li><a href="/esg/social/human-rights" data-href2="#" data-href="#" ><span>Human Rights</span></a></li> <li><a href="/esg/social/compliance" data-href2="#" data-href="#" ><span>Compliance</span></a></li> <li><a href="/esg/social/ethics" data-href2="#" data-href="#" ><span>Business Ethics</span></a></li> <li><a href="/esg/social/csr" data-href2="#" data-href="#" ><span>Corporate Social Responsibility</span></a></li> <li><a href="/esg/social/suppliers" data-href2="#" data-href="#" ><span>Suppliers</span></a></li> <li><a href="/esg/social/bcms" data-href2="#" data-href="#" ><span>BCMS</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/esg/governance/articles" data-href2="#"><span>Governance</span></a> <ul class="depth3"> <li><a href="/esg/governance/articles" data-href2="#" data-href="#" ><span>Articles of Incorporation</span></a></li> <li><a href="/esg/governance/board-structure" data-href2="#" data-href="#" ><span>Board Structure</span></a></li> <li><a href="/esg/governance/bod-committees" data-href2="#" data-href="#" ><span>BOD Committees</span></a></li>  <li><a href="/esg/governance/corporate-governance-report" data-href2="#" data-href="#" ><span>Corporate Governance</span></a></li> <li><a href="/esg/governance/exAuditList" data-href2="/esg/governance/exAuditView" data-href="#" ><span>External Auditor</span></a></li> </ul> </li> </ul> </div> </div> </li> <li> <a href="/ir/overview" data-href2="/front/en/investorRelations/overview.do"><span>Investors</span></a> <div class="depth2Wrap"> <div class="depth2 depth2_4"> <ul> <li> <a href="/ir/overview" data-href2="/front/en/investorRelations/overview.do" ><span>Overview</span></a> </li> </ul> <ul> <li> <a href="/ir/financial-info/financial-snapshot" data-href2="/front/en/investorRelations/financialInformation/financialSnapshot.do"><span>Financial Information</span></a> <ul class="depth3"> <li><a href="/ir/financial-info/financial-snapshot" data-href2="/front/en/investorRelations/financialInformation/financialSnapshot.do" ><span>Financial Snapshot</span></a></li> <li> <a href="/ir/financial-info/financial-statements"><span>Financial Report</span></a> <ul class="depth4"> <li><a href="/ir/financial-info/financial-statements"><span>- Financial Statements</span></a></li> <li><a href="/ir/financial-info/annual-business-report"><span>- Business Report</span></a></li> <li><a href="/ir/financial-info/earning-release"><span>- Earnings Release</span></a></li> </ul> </li> </ul> </li> </ul> <ul> <li> <a href="/ir/stock-info/listing-information" data-href2="/front/en/investorRelations/stockShareholder/listingInformation.do"><span>Stock & Shareholder<br class="pc" /> Information</span></a> <ul class="depth3"> <li><a href="/ir/stock-info/listing-information" data-href2="/front/en/investorRelations/stockShareholder/listingInformation.do" ><span>Listing Information</span></a></li> <li><a href="/ir/stock-info/stock-charts" data-href2="/front/en/investorRelations/stockShareholder/stockCharts.do" ><span>Stock Charts</span></a></li> <li><a href="/ir/stock-info/ownership-structure" data-href2="/front/en/investorRelations/stockShareholder/ownershipStructure.do" ><span>Ownership Structure</span></a></li> <li><a href="/ir/stock-info/general-meeting" data-href2="#" data-href="#" ><span>General Meeting of Shareholders</span></a></li> </ul> </li> </ul>  <ul> <li> <a href="/ir/resource/notice"><span>IR Resource</span></a> <ul class="depth3"> <li><a href="http://engkind.krx.co.kr/disclosure/searchdisclosurebycorp.do?method=searchDisclosureByCorpMain&searchCodeType=char&searchCorpName=Samsung%20biologics" target="_blank" title="window open"><span>Public Disclosures</span></a></li> <li><a href="/ir/resource/notice" data-href2="/ir/resource/notice-view" ><span>IR Notice</span></a></li>  </ul> </li> </ul> </div> </div> </li> <li> <a href="/media/newsroom" data-href2="/front/en/mediaCenter/newsRoom.do"><span>Newsroom</span></a> <div class="depth2Wrap"> <div class="depth2 depth2_5"> <ul> <li><a href="/media/newsroom"><span>Newsroom</span></a></li> </ul> <ul> <li> <a href="/media/company-news" data-href2="/media/company-news-view"><span>Company News</span></a> <ul class="depth3"> <li class="sub_Mnhidden noDepth"><a href="/media/company-news?schBoardCtgryCcd=1"><span>Press Release</span></a></li> <li class="sub_Mnhidden noDepth"><a href="/media/company-news?schBoardCtgryCcd=6"><span>News Brief</span></a></li> <li class="sub_Mnhidden noDepth"><a href="/media/company-news?schBoardCtgryCcd=7"><span>Media Focus</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/media/bio-story" data-href2="/media/bio-story-view"><span>Our Story</span></a> <ul class="depth3"> <li class="sub_Mnhidden noDepth"><a href="/media/bio-story?schBoardCtgryCcd=1"><span>Life @ Samsung Biologics</span></a></li> <li class="sub_Mnhidden noDepth"><a href="/media/bio-story?schBoardCtgryCcd=3"><span>Samsung Bio Insight</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/media/science-technology" data-href2="/front/en/mediaCenter/resourceLibraryList.do" data-href3="/front/en/mediaCenter/resourceLibraryView.do" data-href="/media/science-technology-view"><span>Science & Technology</span></a> <ul class="depth3"> <li class="sub_Mnhidden noDepth"><a href="/media/science-technology?schBoardCtgryCcd=1" data-href2="/front/en/mediaCenter/resourceLibraryList.do?schBoardCtgryCcd=1" data-href3="/front/en/mediaCenter/resourceLibraryView.do?schBoardCtgryCcd=1"><span>Whitepapers</span></a></li> <li class="sub_Mnhidden noDepth"><a href="/media/science-technology?schBoardCtgryCcd=2" data-href2="/front/en/mediaCenter/resourceLibraryList.do?schBoardCtgryCcd=2" data-href3="/front/en/mediaCenter/resourceLibraryView.do?schBoardCtgryCcd=2"><span>Posters</span></a></li> <li class="sub_Mnhidden noDepth"><a href="/media/science-technology?schBoardCtgryCcd=3" data-href2="/front/en/mediaCenter/resourceLibraryList.do?schBoardCtgryCcd=3" data-href3="/front/en/mediaCenter/resourceLibraryView.do?schBoardCtgryCcd=3"><span>Webinars</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/media/pr-materials" data-href2="/front/en/mediaCenter/prMaterials.do"><span>PR Materials</span></a> <ul class="depth3"> <li><a href="/media/pr-materials?tab=1" data-href2="/front/en/mediaCenter/prMaterials.do?tab=1"><span>Brochures & Infographics</span></a></li> <li><a href="/media/pr-materials?tab=2" data-href2="/front/en/mediaCenter/prMaterials.do?tab=2"><span>Company Images</span></a></li> <li class="sub_Mnhidden noDepth"><a href="/media/pr-materials?tab=3" data-href2="/front/en/mediaCenter/prMaterials.do?tab=3" data-href="/media/pr-materials-view"><span>Videos</span></a></li> </ul> </li> </ul> <ul> <li><a href="/media/events" data-href2="/front/en/mediaCenter/upcomingEventsList.do" data-href3="/front/en/mediaCenter/upcomingEventsView.do" data-href="/media/events-view" ><span>Events</span></a></li> </ul>  </div> </div> </li>  </ul> </div> <div class="util type"> <div class="lang">  <ul> <li><a rel="nofollow" href="#" id="language_kr">KOR</a></li> <li><a rel="nofollow" href="#" id="language_en" class="on">ENG<span class="hidden">Selectd</span></a></li> </ul> </div> <button type="button" class="search"><span class="hidden">search</span></button> <div class="newsfeed"> <a href="/media/newsroom" data-id="en"><span class="hidden">NEWSFEED</span></a> </div> <div class="contactUs"> <a href="/contact-us" class="btn"><span class="hidden">Contact Us</span></a> </div>  <a href="#" class="mobile btnMobileMenu"><span class="hidden">mobile menu button</span></a> </div> <form id="gSchFrm" name="gSchFrm" method="get" onsubmit="return gfn_search();"> <div class="searchField"> <div class="pix-in">  <div class="form"> <a href="#" class="btn-search-close">Search Close</a> <ul> <li class="txt"> <label for="gSchString"> <span class="hidden">Enter a search term</span>  <input type="text" id="gSchString" name="schString" placeholder="Enter a search term"> </label> </li> <li class="btn"><input type="submit" title="Search"></li> </ul> </div> </div> </div> </form> </div> <div class="dime"></div> </div> <script type="text/javascript"> $(function(){ $("#mainRoot").on("click", function(){ //console.log("abc"); mainRoot("en"); }); $("#gSchString").keydown(function (key) { if (key.keyCode == 13) { gfn_search(); } }); $("#gmSchString").keydown(function (key) { if (key.keyCode == 13) { gmfn_search(); } }); $("#language_kr").on("click",function () { gfn_lang("KR"); }); }); var gfn_search = function(){ if($("#gSchString").val() == ""){ alert("Enter your search terms"); $("#gSchString").focus(); //return false; }else{ $("#gSchFrm").attr("action","https://partner.samsungbiologics.com/s/931233/s8b8vTLUI20W1ljzKyAi4ePz4UyFvr1S").submit(); } } var gmfn_search = function(){ if($("#gmSchString").val() == ""){ alert("Enter your search terms"); $("#gmSchString").focus(); //return false; }else{ $("#gmSchFrm").attr("action","https://partner.samsungbiologics.com/s/931233/ys1hKha6dMrIKpZ57aQfP6zC2atSWWuP").submit(); } } var str_xss = function(str){ /* return str.replace(/</g, "<").replace(/>/g, ">"); */ return str.replace('&','&').replace('<','<').replace('>','>').replace('"','"').replace("'",'&#x27'); } var mainRoot = function(str){ document.getElementsByName("language")[0].value=str; $("#hFrm").attr('action',"/"); $("#hFrm").submit(); } var gfn_lang = function(str){ var currentUrl = "/esg/governance/board-structure"; if(currentUrl==("/")){ currentUrl = currentUrl.replace("/","/kr"); //for Main Page Trans if("" == "en"){ //location.href ="/?language=kr" document.getElementsByName("language")[0].value="kr"; } $("#hFrm").attr('action',currentUrl); $("#hFrm").submit(); }else{ if(currentUrl.indexOf("/front/en/") != -1) { currentUrl = currentUrl.replace("/front/en/","/front/kr/"); }else{ currentUrl = currentUrl.replace("/","/kr/"); //for static page } currentUrl = currentUrl.replace("/resourceLibraryView.do","/resourceLibraryList.do"); currentUrl = currentUrl.replace("/pressReleasesView.do","/pressReleasesList.do"); currentUrl = currentUrl.replace("/businessLifeView.do","/businessLifeList.do"); currentUrl = currentUrl.replace("/bio-story-view","/bio-story"); currentUrl = currentUrl.replace("/upcomingEventsView.do","/upcomingEventsList.do"); currentUrl = currentUrl.replace("/irNoticeView.do","/irNoticeList.do"); currentUrl = currentUrl.replace("/science-technology-view","/science-technology"); currentUrl = currentUrl.replace("/company-news-view","/company-news"); currentUrl = currentUrl.replace("/business-life-view","/business-life"); currentUrl = currentUrl.replace("/pr-materials-view","/pr-materials?tab=3"); currentUrl = currentUrl.replace("/events-view","/events"); currentUrl = currentUrl.replace("/notice-view","/notice"); currentUrl = currentUrl.replace("/exAuditView","/exAuditList"); //대소문자 수정 currentUrl = currentUrl.replace("/suppliers-view","/suppliers?tabidx=4"); currentUrl = currentUrl.replace("/step2","/step1"); currentUrl = currentUrl.replace("/step3","/step1"); currentUrl = currentUrl.replace("/step4","/step1"); const arr = ["/company-news/", "/bio-story/","/business-life/","/science-technology/"]; arr.forEach(trLink => { currentUrl.indexOf(trLink)>0 ? currentUrl=currentUrl.substr(0,currentUrl.indexOf(trLink)+trLink.length-1):currentUrl; }); currentUrl = currentUrl.replace("/index.do","/index.do?language=kr"); if("" == "en"){ //location.href ="/?language=kr" document.getElementsByName("language")[0].value="kr"; } $("#schLang").val(str); $("#hFrm").attr('action',currentUrl); console.log(currentUrl); $("#hFrm").submit(); } } var gfn_modeChange = function(){ //$("#pcMode").remove(); var content = $('#pcMode').attr('content'); //alert(content); if(content == "width=device-width"){ $('#pcMode').attr('content', 'width=1280'); }else{ $('#pcMode').attr('content', 'width=device-width'); } } </script> <form id="hFrm" name="hFrm" method="post"> <input type="hidden" name="language" /> <input type="hidden" name="schString" value="" /> <input type="hidden" name="searchCd" value="" /> </form> <div id="container">  <div class="sub_visual esgManagement"> <div class="text_area">  <h2 class="jsTit"></h2> </div> </div>    <div class="sub_menu" id="sub_menu"> <div class="sub_menu_area"> <a href="/" class="home">home</a> <div class="subMn"></div> <a href="/contact-us" class="btn_contactUs">CONTACT US</a> </div> </div>  <div id="content"> <div class="pix-in"> <div class="pageTitle"> <h3>Board Structure</h3> </div> <div class="tabBox"> <ul class="tab_area"> <li class="active tab1"><a href="#" data-tab="tab1">Composition of the BOD</a></li> <li class="tab2"><a href="#" data-tab="tab2">Operation and Duties</a></li> <li class="tab3"><a href="#" data-tab="tab3">Activity of the BOD</a></li> </ul> <span class="select_box"> <label> <span class="hidden">Cotent tab</span> <select id="tab_select"> <option value="tab1">Composition of the BOD</option> <option value="tab2">Operation and Duties</option> <option value="tab3">Activity of the BOD</option> </select> </label> </span> </div> </div> <div data-activetab="tab1" class="tab_cont active"> <div class="pix-in"> <strong class="hidden">Composition of the BOD</strong> <div class="pageTitle"> <p>The board of directors is composed of seven members consisting of three directors and four independent directors. Independent directors have no ties to the company either through transactions or as a former employee or inside director.</p> </div> <ul class="directors_list">  <li> <div class="thumb pc tableCell"><img src="/resources/front/en/images/investors/img_directors_list06.png" alt="Executive Vice President / John Rim"></div> <dl> <dt> President & CEO, <br />Chairman of the board </dt> <dd> John Rim  </dd> </dl> <ul class="directors_info"> <li><strong>President & CEO, Samsung Biologics </strong>(2020-Present)</li> <li><strong>Executive Vice President, CMO2 Center, <br class="pc" />Samsung Biologics </strong>(2018-2020)</li> <li><strong>Vice President, Global Product Development Procurement, Roche </strong>(2014-2018)</li> <li><strong>Vice President, CFO Global Product Development, Roche </strong>(2010-2013)</li> </ul> <div class="thumb mobile block"><img src="/resources/front/en/images/investors/m_img_directors_list06.png" alt="Executive Vice President / John Rim"></div> <div class="termExpiration"> <ul> <li> <strong>Date of first appointment :</strong> <span>March 20, 2020</span> </li> <li> <strong>Term expiration :</strong> <span>March 16, 2026</span> </li> </ul> </div> </li> <li> <div class="thumb pc tableCell"><img src="/resources/front/en/images/investors/img_directors_list02.png" alt="EXECUTIVE VICE PRESIDENT / Dong joong Kim"></div> <dl> <dt>EXECUTIVE VICE PRESIDENT</dt> <dd>Dong Joong Kim</dd> </dl> <ul class="directors_info"> <li><strong>Executive Vice President, <br class="pc"> Business Support Center, Samsung Biologics </strong>(2014-Present)</li> <li><strong>Head of Planning Support Team, <br>Production Technology Institute, <br>Samsung Electronics</strong>(2013-2014)</li> </ul> <div class="thumb mobile block"><img src="/resources/front/en/images/investors/m_img_directors_list02.png" alt="EXECUTIVE VICE PRESIDENT / Dong joong Kim"></div> <div class="termExpiration"> <ul> <li> <strong>Date of first appointment :</strong> <span>August 10, 2016</span> </li> <li> <strong>Term expiration :</strong> <span>March 28, 2025</span> </li> </ul> </div> </li> <li> <div class="thumb pc tableCell"><img src="/resources/front/en/images/investors/img_directors_list10.jpg" alt="EXECUTIVE VICE PRESIDENT / Kun Lo"></div> <dl> <dt>EXECUTIVE VICE PRESIDENT</dt> <dd>Kun Lo</dd> </dl> <ul class="directors_info"> <li><strong>Executive Vice President,<br />EPCV Center, Samsung Biologics</strong>(2021~Present)</li> <li><strong>Head of DS Center, Samsung Biologics</strong>(2020~2021)</li> <li><strong>Head of New Business Division, Samsung Engineering</strong>(2013~2020)</li> </ul> <div class="thumb mobile block"><img src="/resources/front/en/images/investors/m_img_directors_list10.jpg" alt="EXECUTIVE VICE PRESIDENT / Kun Lo"></div> <div class="termExpiration"> <ul> <li> <strong>Date of first appointment :</strong> <span>March 17, 2023</span> </li> <li> <strong>Term expiration :</strong> <span>March 16, 2026</span> </li> </ul> </div> </li>  <li> <div class="thumb pc tableCell"><img src="/resources/front/en/images/investors/img_directors_list03.png" alt="Independent director / Geunnyeong Heo"></div> <dl> <dt>Independent Director</dt> <dd>Geunnyeong Heo</dd> </dl> <ul class="directors_info"> <li><strong>Independent Director, <br> Samsung Biologics</strong>(2019-Present)</li> <li><strong>Advisor, Pyeong An Lawfirm</strong>(2019-Present)</li> <li><strong>Presiding Judge, <br> Seoul Central District Court </strong>(2004-2007)</li> </ul> <div class="thumb mobile block"><img src="/resources/front/en/images/investors/m_img_directors_list03.png" alt="Independent director / Geunnyeong Heo"></div> <div class="termExpiration"> <ul> <li> <strong>Date of first appointment :</strong> <span>March 22, 2019</span> </li> <li> <strong>Term expiration :</strong> <span>March 28, 2025</span> </li> </ul> </div> </li> <li> <div class="thumb pc tableCell"><img src="/resources/front/en/images/investors/img_directors_list07.png" alt="INDEPENDENT DIRECTOR / Eunice Kyonghee Kim"></div> <dl> <dt>Independent Director</dt> <dd> Eunice Kyonghee Kim <div class="btn"> <a href="https://www.youtube.com/watch?v=I2O6CRQ3NKc" target="_blank" title="Window Open" >Watch the Interview</a> </div> <div> <iframe src="https://www.youtube.com/embed/I2O6CRQ3NKc?&enablejsapi=1&rel=0" title="Watch the Interview Movie View" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen style="width: 100%; margin-top: 20px;"></iframe> </div> </dd> </dl> <ul class="directors_info"> <li><strong>Independent Director, Samsung Biologics </strong>(2020-Present)</li> <li><strong>Professor, Law School, Ewha Women's University </strong>(2010-2021)</li> <li><strong>Vice president, International Association of Korean Lawyers (IAKL) </strong>(2008-Present)</li> <li><strong>Deputy-CEO and Chief Legal & Compliance Officer, Hana Financial Group, Inc. </strong>(2008-2010)</li> </ul> <div class="thumb mobile block"><img src="/resources/front/en/images/investors/m_img_directors_list07.png" alt="Independent director / Eunice Kyunghee Kim"></div> <div class="termExpiration hasVideo"> <ul> <li> <strong>Date of first appointment :</strong> <span>March 20, 2020</span> </li> <li> <strong>Term expiration :</strong> <span>March 16, 2026</span> </li> </ul> </div> </li> <li> <div class="thumb pc tableCell"><img src="/resources/front/en/images/investors/img_directors_list08.png" alt="Independent director / Changwoo Lee"></div> <dl> <dt>Independent Director</dt> <dd>Changwoo Lee</dd> </dl> <ul class="directors_info"> <li><strong>Independent Director, Samsung Biologics</strong>(2022-Present)</li> <li><strong>Emeritus Faculty, Business School, <br>Seoul National University</strong>(2019-Present)</li> <li><strong>Chairman of the Ethics Committee, <br>Korean Accounting Standard Board</strong>(2020-Present)</li> </ul> <div class="thumb mobile block"><img src="/resources/front/en/images/investors/m_img_directors_list08.png" alt="Independent director / Changwoo Lee"></div> <div class="termExpiration"> <ul> <li> <strong>Date of first appointment :</strong> <span>March 29, 2022</span> </li> <li> <strong>Term expiration :</strong> <span>March 28, 2025</span> </li> </ul> </div> </li> <li> <div class="thumb pc tableCell"><img src="/resources/front/en/images/investors/img_directors_list12.png" alt="Independent Director / Seoung Hwan Suh"></div> <dl> <dt>Independent Director</dt> <dd>Seoung Hwan Suh</dd> </dl> <ul class="directors_info"> <li><strong>Current Professor Emeritus at Yonsei University</strong>(2024-Present)</li> <li><strong>19th President, Yonsei University</strong>(2020-2024)</li> <li><strong>Minister for Ministry of Land, Infrastructure, and Transport</strong>(2013-2015)</li> <li><strong>18th Korea Presidential Transition Committee, Committee Member of the Economics Division 2</strong>(2013)</li> </ul> <div class="thumb mobile block"><img src="/resources/front/en/images/investors/m_img_directors_list12.png" alt="Independent Director / Seoung Hwan Suh"></div> <div class="termExpiration"> <ul> <li> <strong>Date of first appointment :</strong> <span>March 15, 2024</span> </li> <li> <strong>Term expiration :</strong> <span>March 14, 2027</span> </li> </ul> </div> </li>   </ul> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Appointment of Directors</h4> <p class="desc">Members of the board of directors are elected through a resolution of the general meeting of shareholders under the company’s articles of incorporation. Incumbent members may be reelected after the expiration of their terms.</p> <ul class="dot_list fc_gray_666"> <li>Samsung Biologics shall have at least three but no more than ten directors and such directors shall be appointed at the general meeting of shareholders; provided, however, that at least three independent directors shall be appointed and the number of the independent directors shall account for at least a majority of the total number of directors.</li> <li>A resolution for the election of directors shall be adopted by the affirmative votes of a majority of the shareholders present at the meeting, which shall also be at least 1/4 of the total number of issued and outstanding shares.</li> <li>Any vacancy in the office of directors shall be filled at a general meeting of shareholders; provided, however, that if the number of directors does not fall below the number prescribed in Paragraph 1 of Article 29 in the Articles of Incorporation and there is no difficulty in the administration of business, the foregoing shall not be applicable.</li> </ul> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Term of Office of Director</h4> <p class="desc">The term of office of directors shall end at the close of the ordinary general meeting of shareholders convened in respect to the last fiscal year within three years from their appointment.</p> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Chairperson</h4> <p class="desc">The chairperson of the board of directors shall be appointed among the directors by a resolution of the board of directors.</p> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Resolution of the BOD</h4> <p class="desc">The resolution of the board of directors shall be adopted in the attendance of a majority of the directors in the office and by the affirmative votes of a majority of the directors present at the meeting; provided, however, that a resolution of the board of directors on matters stipulated under Article 397-2 (Prohibition of Use of Corporate Opportunities and Assets) and Article 398 (Self-Dealing between Directors, etc. and the Company) of the Commercial Code shall be adopted by the affirmative votes of at least 2/3 of the directors in office.</p> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Independence of Independent Directors</h4> <p class="desc">The Independent Director Candidate Nomination Committee shall nominate the candidates for the independent directors among persons who meet qualification requirements stipulated in the relevant laws and regulations, including the Commercial Code, etc.</p> <ul class="dot_list fc_gray_666"> <li>An independent director shall be one with professional knowledge or sufficient experience in management, economics, accounting, law or relevant technology and duly qualified under the relevant law. He or she shall not be a current employee or director or a previous employee or director of the company or its affiliate (as stipulated in the Monopoly Regulation and Fair Trade Act) within the past two years, a major shareholder of the company or one with a special relationship with a major shareholder.</li> </ul> </div> </div> </div> <div data-activetab="tab2" class="tab_cont"> <div class="pix-in"> <strong class="hidden">Operation and Duties</strong> <div class="pageTitle"> <p>The board of directors shall be divided into an ordinary and extraordinary board. <br class="pc">In principle the chairperson convenes the board of directors meeting, and if it is deemed necessary for administration of business, any director may convene the board of directors meeting with the consent of the chairperson. </p> <a href="javascript:downloadFileSub('boardStructure_eng.pdf', 'boardStructure.pdf','files');" class="btn_download line2" title="Download"><span>BOD Operation Rules PDF Download</span></a>  </div> <div class="border_wrap first"> <h4 class="border_tit t_uppercase">Meetings of the BOD</h4> <p class="desc">The board of directors shall be divided into an ordinary and extraordinary board.</p> <ul class="dot_list fc_gray_666"> <li><strong>Ordinary Board of Directors :</strong> The meeting of ordinary board of directors is held once a quarter. The chairperson of the board of directors shall set the date and call for the meeting.</li> <li><strong>Extraordinary Board of Directors :</strong> The meeting of extraordinary board of directors may be held from time to time as required.</li> </ul> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Convening of BOD Meeting</h4> <p class="desc">In principle the chairperson convenes the board of directors meeting, and if it is deemed necessary for administration of business, any director may convene the board of directors meeting with the consent of the chairperson. </p> <ul class="dot_list fc_gray_666"> <li><strong>Procedure : </strong> The chairperson shall set a date and time of the meeting of the board of directors and give a notice to each director no later than twenty four hours prior to the meeting in writing, electronic document, or orally; provided, however, that such notice may be waived with the unanimous consent of all directors.</li> </ul> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Resolution of the BOD</h4> <p class="desc">The resolution of the board of directors shall be adopted in the attendance of a majority of the directors in office and by the affirmative votes of a majority of the directors present at the meeting.</p> <ul class="dot_list fc_gray_666"> <li>The board of directors may allow all or a part of the directors who do not attend a meeting in person to participate in a resolution through communication that concurrently transmits and receives voices of all directors. In this case, such director shall be deemed to have attended the board of directors meeting in person.</li> <li>A director with his or her own interests in a resolution of the board of directors shall not be allowed to participate in voting.</li> </ul> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">BOD Operation Rules</h4> <div class="faqList" data-accordion> <dl class="list chapterList"> <dt><a href="#" title="Open"><span>Article 1</span>Purpose</a></dt> <dd class="txt-cont" style="display:none;"> <ul> <li>The purpose of these Rules and Regulations of the Board of Directors (the “Rules”) is to provide for matters pertaining to the operation of the Board of Directors (hereinafter referred to as the “BOD”) of Samsung Biologics Co., Ltd. (referred to as the “Company” hereinafter) in accordance with the relevant laws and regulations and the Articles of Incorporation (hereinafter referred to as the “AOI”).</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 2</span>Scope of Applications</a></dt> <dd class="txt-cont"> <ul> <li>With respect to matters pertaining to the BOD, these rules and regulations shall apply unless those stipulated otherwise in the relevant laws or the AOI.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 3</span>Authority</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>The BOD shall deliberate and resolve matters stipulated in the relevant laws or the AOI, matters authorized by the general meeting of shareholders, and important issues concerning basic policies and execution of business related to the management of the Company.</li> <li><span class="num">②</span>The BOD shall supervise the directors’ execution of duty.</li> <li><span class="num">③</span>When it is determined that a director has violated a provision of the laws or the AOI in performing his/her duties, or performed such duties in a substantially improper manner, or the BOD recognizes that there is a concern that such director will perform his/ her duties in a substantially improper manner, the BOD may request such director to submit relevant data, cooperate on investigation, and/or provide explanation.</li> <li><span class="num">④</span>If any of the events in Paragraph 3 occurs, the BOD may require the relevant director to suspend or change the performance of relevant duties.</li> <li><span class="num">⑤</span>Any director may request the representative director to report performance of other directors or employees to the BOD.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 4</span>Composition</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>The BOD shall be comprised of all directors.</li> <li><span class="num">②</span>The term of office of a director shall expire at the close of the ordinary general meeting of shareholders held for the third fiscal period from the inauguration of the applicable director.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 5</span>Chairperson</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>The chairperson of the BOD shall be appointed among the directors by a resolution of the BOD.</li> <li><span class="num">②</span>The term of office of the chairperson shall end at the expiration of the term of office of the applicable director.</li> <li><span class="num">③</span>When the chairperson is unable to perform his/her duties, the director that was first appointed among all of the directors of the BOD shall act as the chairperson; provided, however, that if two (2) or more directors were appointed on the same date, the most senior director shall act as the chairperson.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 6</span>Convening of BOD Meeting</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>The meetings of the BOD shall be either ordinary meetings or extraordinary meetings.</li> <li><span class="num">②</span>Ordinary meetings of the BOD shall, in principle, be convened once each quarter.</li> <li><span class="num">③</span>Extraordinary meetings of the BOD shall be convened on an ad-hoc basis when deemed necessary.</li> <li><span class="num">④</span>The chairperson of the BOD shall set a date and time of the meeting of the BOD, and provide written, electronic, or oral notice to each director no later than 24 hours in advance of such meeting; provided, however, that such convocation procedure may be omitted upon unanimous consent of the directors.</li> <li><span class="num">⑤</span>If it is deemed necessary for carrying out the business of the Company, any director may convene a meeting of the BOD upon the consent of the chairperson. In this case, the provisions in Paragraph 4 above shall apply mutatis mutandis.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 7</span>Method of Resolution</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>Unless stipulated otherwise in the relevant laws and regulations, the BOD resolutions shall be done in accordance with Paragraphs 1 through 3 of Article 38 of the AOI.</li> <li><span class="num">②</span>Unless stipulated otherwise in the relevant laws and regulations, the number of directors who cannot exercise his/her vote in accordance with Article 38, Paragraph 3 of the AOI shall not be included in the number of directors present at the meeting.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 8</span>Agenda</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li> <span class="num">①</span>The following matters shall be resolved by the BOD: <ul class="num-list"> <li> <span class="num">1.</span>Convening of the general meeting of shareholders and matters for resolution to be submitted thereto <div> <span>【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】</span> <ul class="num-list"> <li><span class="num">1)</span>Convening of the general meeting of shareholders</li> <li><span class="num">2)</span>Approval of financial statements</li> <li><span class="num">3)</span>Approval of annual report</li> <li><span class="num">4)</span>Distribution of profits</li> <li><span class="num">5)</span>Amendment to the AOI</li> <li><span class="num">6)</span>Capital reduction</li> <li><span class="num">7)</span>Dissolution, amalgamation, spin-off, merger through spin-off, continuation of company (Article 519 of the Commercial Code)</li> <li><span class="num">8)</span>Assignment of the businesses of the Company in whole or in material part; acquisition in whole or in part of another company’s business having a material impact on the business of the Company</li> <li><span class="num">9)</span>Lease or entrustment of management business in whole; execution of contract where all profits and losses are shared with a 3rd party (each a “Shared Contract”); execution, amendment, or termination of another contract that is commensurate to a Shared Contract</li> <li><span class="num">10)</span>Ex-post incorporation</li> <li><span class="num">11)</span>Appointment and dismissal of directors</li> <li><span class="num">12)</span>Remuneration of directors</li> <li><span class="num">13)</span>Issuance of shares at less-than-face value</li> <li><span class="num">14)</span>Acquisition of treasury shares</li> <li><span class="num">15)</span>Decision on stock dividends</li> <li><span class="num">16)</span>Stock-split and stock-consolidation of shares</li> <li><span class="num">17)</span>Waiver of a director’s liability toward the Company upon unanimous consent of the shareholders</li> <li><span class="num">18)</span>Redemption of shares</li> <li><span class="num">19)</span>Total share swap</li> <li><span class="num">20)</span>Total share transfer</li> <li><span class="num">21)</span>Granting of stock options</li> <li><span class="num">22)</span>Other agenda items to be submitted to the general meeting of shareholders and material issues concerning shares</li> </ul> </div> </li> <li> <span class="num">2.</span>Matters pertaining to management <div> <span>【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】</span> <ul class="num-list"> <li><span class="num">1)</span>Decision on short form merger, short form merger through spin-off, small-scale mergers, and small-scale merger through spin-off</li> <li><span class="num">2)</span>Execution and reporting of asset revaluation</li> </ul> </div> <div> <span>【Other important matters pertaining to the management of the Company】</span> <ul class="num-list"> <li><span class="num">1)</span>Establishment and revision of basic policies on the management of the Company</li> </ul> </div> </li> <li> <span class="num">3.</span>Matters pertaining to finance <div> <span>【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】</span> <ul class="num-list"> <li><span class="num">1)</span>Disposition or redemption of treasury shares</li> <li><span class="num">2)</span>Issuance of new shares</li> <li><span class="num">3)</span>Issuance of corporate bonds, convertible bonds, or bonds with warrants</li> <li><span class="num">4)</span>Capitalization of reserves</li> <li><span class="num">5)</span>Allocation of new shares to a 3rd party</li> <li><span class="num">6)</span>Distribution of interim dividends</li> <li><span class="num">7)</span>Transaction with a “specially-related party” as set forth in the Commercial Code or large-scale transaction for a “specially-related party”</li> <li><span class="num">8)</span>Handling of forfeited shares in case of capitalization by issuing new shares</li> </ul> </div> <div> <span>【Other important matters pertaining to finance】</span> <ul class="num-list"> <li><span class="num">1)</span>Foreign direct investment valued at 2.5% or more of the equity capital of the Company</li> <li><span class="num">2)</span>Listing of shares or depository certificates in a foreign stock exchange</li> <li><span class="num">3)</span>Borrowing valued at 2.5% or more of the equity capital of the Company</li> <li><span class="num">4)</span>Acquisition or waiver of debt valued at 2.5% or more of the equity capital of the Company per transaction</li> <li><span class="num">5)</span>Offering of security or guarantee of debt valued at 2.5% or more of the equity capital of the Company per transaction</li> <li><span class="num">6)</span>Donation or sponsorship valued at KRW 100 million or more</li> <li><span class="num">7)</span>Other important financial matters to be submitted to the BOD</li> </ul> </div> </li> <li> <span class="num">4.</span>Matters pertaining to directors, the BOD, committees, etc. <div> <span>【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】</span> <ul class="num-list"> <li><span class="num">1)</span>Appointment of the representative director</li> <li><span class="num">2)</span>Appointment of the chairperson of the BOD in case the representative director is unable to serve as the chairperson</li> <li><span class="num">3)</span>Establishment and operation of a committee(s) within the BOD, appointment and dismissal of a committee member</li> <li><span class="num">4)</span>Approval of a director serving as a concurrent director at another company that competes with or operates in the same industry as the Company and approval of transaction between a director, etc., and the Company</li> <li><span class="num">5)</span>Re-resolution of an agenda item for resolution by a committee within the BOD</li> <li><span class="num">6)</span>Appointment or dismissal of a director from a specific position or duty</li> </ul> </div> <div> <span>【Other important matters pertaining to directors, the BOD, committees, etc.】</span> <ul class="num-list"> <li><span class="num">1)</span>Enforcement or nullification of the Rules and Regulations of the Board of Directors or the rules and regulations of committees within the BOD (operational guidelines)</li> </ul> </div> </li> <li> <span class="num">5.</span>Others <ul class="num-list"> <li><span class="num">1)</span>Other matters set forth in the relevant laws and regulations or the AOI, authorized and delegated by the general meeting of shareholders, or deemed necessary by the representative director</li> </ul> </li> </ul> </li> <li> <span class="num">②</span>The following matters shall be reported to the BOD: <ul class="num-list"> <li><span class="num">1.</span>Matters that have been delegated to a committee(s) within the BOD and how such matters were decided / resolved</li> <li><span class="num">2.</span>Matters for which the Audit Committee has determined that a director has or there is a concern that a director may violate the relevant laws or the AOI</li> <li><span class="num">3.</span>Other matters pertaining to the execution of matters that are considered important to the operations of the Company</li> </ul> </li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 9</span>Delegation of Authority</a></dt> <dd class="txt-cont"> <ul> <li>Unless stipulated otherwise in the relevant laws and regulations or the AOI, the representative director or a committee authorized by the BOD under Article 10 may be delegated with the authority to make decisions on matters that require a resolution of the BOD.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 10</span>Committees under BOD</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>Committees within the BOD shall be subject to Article 37 of the AOI; provided, however, that with respect to the Audit Committee, Chapter 6 (Audit Committee) of the AOI shall first apply.</li> <li><span class="num">②</span>The Management Committee shall operate in compliance with the rules and resolutions of the BOD, and in addition, deliberate on and resolve matters delegated by the BOD from time to time.</li> <li><span class="num">③</span>Unless they are in conflict with Paragraph 1 of this Article 10 and the rules of applicable committee within the BOD, Article 38 of the AOI shall apply mutatis mutandis to the committee(s) within the BOD. In such provisions of the AOI, “BOD” shall mean applicable “committee within the BOD” and “Director” shall mean a “member of such committee.”</li> <li><span class="num">④</span>Notwithstanding anything stated in Paragraph 3 of Article 10, matters set forth in Article 397-2 (Restriction on Abuse of Corporate Opportunities and Assets of the Company) and Article 398 (Transactions between Directors, Etc., and the Company) of the Commercial Code shall be adopted by two-thirds or more of the registered directors of the BOD.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 11</span>Counsel of Relevant Persons</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>In deliberating on an agenda item, the BOD may invite a relevant officer or employee of the Company or a third party to attend the BOD meeting and explain the agenda item or provide his/her opinion.</li> <li><span class="num">②</span>The BOD may, at the cost of the Company, resolve to engage an expert or other similar individual to consult on a particular agenda item, if it finds such a service necessary.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 12</span>Meeting Minutes</a></dt> <dd class="txt-cont"> <ul> <li>Meeting minutes shall be prepared for BOD meetings and meetings of any committee within the BOD, and such meeting minutes shall set forth the agenda, proceedings of the meeting, results, objecting party and reason(s) for objection, and be affixed with the seal impressions of or signed by the directors present at the meeting.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 13</span>Ratification</a></dt> <dd class="txt-cont"> <ul> <li>If an issue is urgent, and there is insufficient time to convene a meeting of the BOD, so long as and to the extent it does not violate the relevant laws and regulations, the representative director shall perform the necessary action and convene a meeting of the BOD after the fact where he/she shall report the progress of such action and obtain the BOD’s ratification.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 14</span>Secretary</a></dt> <dd class="txt-cont"> <ul class="num-list typ2"> <li><span class="num">①</span>The BOD shall have a secretary who shall be appointed by the chairperson.</li> <li><span class="num">②</span>The chairperson of the BOD shall instruct and supervise the secretary. The secretary shall assist each director of the BOD and administer the overall operations of the BOD.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 15</span>Expenses</a></dt> <dd class="txt-cont"> <ul> <li>Expenses necessary for meetings and other operations shall be borne by the Company.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Article 16</span>Enactment and Nullification of the Rules</a></dt> <dd class="txt-cont"> <ul> <li>These Rules shall be enacted and nullified by a resolution of the BOD.</li> </ul> </dd> <dt><a href="#" title="Open"><span>Addendum</span></a></dt> <dd class="txt-cont"> <ul> <li> <span>Article 1 (Effective Date)</span> </li> <li>These Rules shall become effective on August 10, 2016.</li> </ul> </dd> </dl> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">Major Agenda items</h4> <p class="desc">1. A director with his or her own interests in a resolution of the board of directors shall not be allowed to participate in voting.</p> <ul class="dot_list fc_gray_666"> <li>Convening of the general meeting of shareholders</li> <li>Approval of financial statements</li> <li>Approval of annual report</li> <li>Amendment to the AOI</li> <li>Dissolution, amalgamation, continuation of company</li> <li>Assignment of the businesses of the company in whole or in material part; acquisition in whole or in part of another company’s business having a material impact on the business of the company.</li> <li>Appointment and dismissal of directors</li> <li>Remuneration of directors, etc.</li> </ul> <p class="desc">2. Matters pertaining to management</p> <ul class="dot_list fc_gray_666"> <li>Matters pertaining to management</li> <li>Enforcement or nullification of the Rules and Regulations of the Board of Directors or the rules and regulations of committees within the BOD</li> </ul> <p class="desc">3. Matters pertaining to finance</p> <ul class="dot_list fc_gray_666"> <li>Disposition or redemption of treasury shares</li> <li>issuance of new shares</li> <li>Issuance of corporate bonds, convertible bonds, or bonds with warrants</li> <li>Foreign direct investment, borrowing, acquisition or waiver of debt, offering of security or guarantee of debt, etc.</li> <li>Transaction with a “specially-related party” as set forth in the Commercial Code or large-scale transaction for a “specially-related party”, etc.</li> <li>Donation or sponsorship</li> </ul> <p class="desc">4. Matters pertaining to directors, the BOD, committees, etc.</p> <ul class="dot_list fc_gray_666"> <li>Appointment of the representative director</li> <li>Appointment of the chairperson of the BOD</li> <li>Approval of a director serving as a concurrent director at another company that competes with or operates in the same industry as the Samsung iologics and approval of transaction between a director, etc., and Samsung Biologics</li> <li>Appoint or dismissal of a director from a specific position or duty</li> </ul> <p class="desc">5. Others</p> <ul class="dot_list fc_gray_666"> <li>Other matters set forth in the relevant laws and regulations or the AOI, authorized and delegatedby the general meeting of shareholders, or deemed necessary by the representative director</li> </ul> </div> </div> </div> <div data-activetab="tab3" class="tab_cont "> <div class="pix-in"> <strong class="hidden">Activity of the BOD</strong> <div class="pageTitle"> <p>Activity of the BOD includes the status of the board of directors' activities such as appointment, commissioning, approval, participation, decision, revision, enforcement, reporting and issuance.</p> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2023</h4> <div class="pc block"> <table class="col_table"> <caption>2023 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="7" class="vt-t">DEC. 20, 2023</td> <td>(Reported) 2023 Employee incentive provision plan</td> <td class="fc_black">-</td> <td rowspan="7" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Amendments on operation policy of Board of Directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Appointment of lead independent director</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Approval of charity donation</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">6. Nomination of Board of Director's committee members</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="6" class="vt-t">OCT. 25, 2023</td> <td>(Reported) 3Q 2023 interim business result</td> <td class="fc_black">-</td> <td rowspan="6" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of purchasing package insurance from Samsung Fire & Marine Insurance Co.,Ltd</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of New Technology Investment Association</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of investment in construction of ADC facility</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Appointment of internal compliance auditor</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="4" class="vt-t">JUL. 26, 2023</td> <td>(Reported) 1H 2023 interim business result</td> <td class="fc_black">-</td> <td rowspan="4" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">(Reported) Report on increased legal fees and expenses associated with the accounting lawsuit</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Regulation of responsibility and authority for Chief Safety Officer (CSO)</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="3" class="vt-t">APR. 24, 2023</td> <td>(Reported) 1Q 2023 interim business result</td> <td class="fc_black">-</td> <td rowspan="3" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">(Reported) 2023 ESG management plan</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="8" class="vt-t">MAR. 17, 2023</td> <td>(Reported) Progress on important matters</td> <td class="fc_black">-</td> <td rowspan="8" class="vt-m ta-c">6/7</td> </tr> <tr> <td><span class="indent_num">(Reported) 2023 health and safety plan</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Nomination of Chief Executive Officer</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Nomination of Board of Director’s chairman</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Nomination of Board of Director's committeemembers</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Review of compensation for directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">6. Approval of investment for Plant 5 construction</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">FEB. 15, 2023</td> <td>(Reported) Operation status of internal control over financial reporting</td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">5/6</td> </tr> <tr> <td><span class="indent_num">(Reported) Assessment on internal control over financial reporting and audit report</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">(Reported) 2022 audit performance report</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Approval of amendments to internal control management</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of convocation and objectives of general meetings of shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">JAN. 27, 2023</td> <td>(Reported) Progress on important matters</td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">6/6</td> </tr> <tr> <td><span class="indent_num">1. Approval of FY2022 financial statements, annual business report, and 2023 business plan</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>DEC. 20, 2023 Activity of the BOD - Date, Attendance, Agenda, Result</caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 20, 2023 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 2023 Employee incentive provision plan</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Amendments on operation policy of Board of Directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Appointment of lead independent director</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Approval of charity donation</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>6. Nomination of Board of Director's committee members</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 25, 2023 Activity of the BOD - Date, Attendance, Agenda, Result</caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 25, 2023 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 3Q 2023 interim business result</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of purchasing package insurance from Samsung Fire & Marine Insurance Co.,Ltd</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of New Technology Investment Association</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of investment in construction of ADC facility</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Appointment of internal compliance auditor</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 26, 2023 Activity of the BOD - Date, Attendance, Agenda, Result </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 26, 2023 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 1H 2023 interim business result</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Report on increased legal fees and expenses associated with the accounting lawsuit</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Regulation of responsibility and authority for Chief Safety Officer (CSO)</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>APR. 24, 2023 Activity of the BOD - Date, Attendance, Agenda, Result</caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">APR. 24, 2023 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 1Q 2023 interim business result</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 2023 ESG management plan</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 17, 2023 Activity of the BOD - Date, Attendance, Agenda, Result</caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 17, 2023 <span class="unit">Attendance 6/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Progress on important matters</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 2023 health and safety plan</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Nomination of Chief Executive Officer</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Nomination of Board of Director’s chairman</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Nomination of Board of Director's committeemembers</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Review of compensation for directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>6. Approval of investment for Plant 5 construction</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 15, 2023 Activity of the BOD - Date, Attendance, Agenda, Result</caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 15, 2023 <span class="unit">Attendance 5/6</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Operation status of internal control over financial reporting</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Assessment on internal control over financial reporting and audit report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 2022 audit performance report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of amendments to internal control management</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of convocation and objectives of general meetings of shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 27, 2023 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 27, 2023 <span class="unit">Attendance 6/6</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Progress on important matters</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2022 financial statements, annual business report, and 2023 business plan</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2022</h4> <div class="pc block"> <table class="col_table"> <caption>2022 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="3" class="vt-t">DEC. 21, 2022</td> <td>(Reported) FY2022 incentive payment plan report</td> <td class="fc_black">-</td> <td rowspan="3" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="2" class="vt-t">NOV. 30, 2022</td> <td><span class="indent_num">1. Approval of charitable contributions</span></td> <td class="fc_black">Approved</td> <td rowspan="2" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">OCT. 26, 2022</td> <td>(Reported) Legal services fee for accounting issues litigation</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td rowspan="6" class="vt-t">OCT. 26, 2022</td> <td>(Reported) FY2022 3rd quarter earnings report</td> <td class="fc_black">-</td> <td rowspan="6" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Joining a financial instrument of Samsung Fire & Marine Insurance</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of anti-corruption guidelines</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Approval of charitable contributions</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Amendment to operational regulations of ESG Committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">JUL. 27, 2022</td> <td>(Reported) FY2022 half year earnings report</td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) Progress of important matters </td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Approval of implementation of Anti-bribery management systems (ISO37001)</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="4" class="vt-t">APR. 27, 2022</td> <td>(Reported) FY2022 1st quarter earnings report </td> <td class="fc_black">-</td> <td rowspan="4" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) Progress of important matters </td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="4" class="vt-t">MAR. 29, 2022</td> <td><span class="indent_num">(Reported) Appointment of members of committees within the BOD</span></td> <td class="fc_black">Approved</td> <td rowspan="4" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Setting the remuneration of Directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of contract to purchase land for Bio Campus II</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of 2022 Safety and Health management system</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="7" class="vt-t">FEB. 25, 2022</td> <td>(Reported) FY2021 Audit Committee activities </td> <td class="fc_black">-</td> <td rowspan="7" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) Operation status of internal accounting management system</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) Evaluation and audit report of internal accounting management system</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) FY2021 Audit performance report </td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) Approval of payment of legal services fee for management’s litigation</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) Assignment of employee stock ownership</td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Decision to convene the 11th(FY2021) AGM</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="2" class="vt-t">JAN. 28, 2022</td> <td><span class="indent_num">1. Signed stock purchase agreement</span></td> <td class="fc_black">Approved</td> <td rowspan="2" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">2. Paid-in capital increase</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">JAN. 27, 2022</td> <td><span class="indent_num">1. Cancellation of signed stock purchase agreement and paid-in capital increase resolution</span></td> <td class="fc_black">Approved</td> <td class="vt-m ta-c">5/7</td> </tr> <tr> <td rowspan="2" class="vt-t">JAN. 27, 2022</td> <td><span class="indent_num">1. Signed stock purchase agreement</span></td> <td class="fc_black">Approved</td> <td rowspan="2" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">2. Paid-in capital increase</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="4" class="vt-t">JAN. 24, 2022</td> <td>(Reported) Report of shareholders' dividend policy</td> <td class="fc_black">-</td> <td rowspan="4" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of FY2021 financial statements and annual business report</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of charitable contribution of idle raw materials</span></td> <td class="fc_black">Approved</td> </tr> </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>DEC. 21 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 21 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2022 incentive payment plan report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>NOV. 30 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">NOV. 30 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of charitable contributions</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 26 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 26 2022 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Legal services fee for accounting issues litigation</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 26 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 26 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2022 3rd quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Joining a financial instrument of Samsung Fire & Marine Insurance</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of anti-corruption guidelines</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Approval of charitable contributions</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Amendment to operational regulations of ESG Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 27 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 27 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2022 half year earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Progress of important matters</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of implementation of Anti-bribery management systems (ISO37001)</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>APR. 27 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">APR. 27 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2022 1st quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Progress of important matters</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 29, 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 29, 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Appointment of members of committees within the BOD</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Setting the remuneration of Directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of contract to purchase land for Bio Campus II</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of 2022 Safety and Health management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 25, 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 25, 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2021 Audit Committee activities </td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Operation status of internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Evaluation and audit report of internal accounting management system </td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2021 Audit performance report </td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Approval of payment of legal services fee for management’s litigation </td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Assignment of employee stock ownership </td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Decision to convene the 11th(FY2021) AGM</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 28, 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 28, 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Signed stock purchase agreement</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Paid-in capital increase</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 27, 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 27, 2022 <span class="unit">Attendance 5/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Cancellation of signed stock purchase agreement and paid-in capital increase resolution</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 27, 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 27, 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Signed stock purchase agreement</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Paid-in capital increase</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 24, 2022 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 24, 2022 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Report of shareholders' dividend policy</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2021 financial statements and annual business report</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of charitable contribution of idle raw materials</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2021</h4> <div class="pc block"> <table class="col_table"> <caption>2021 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="4" class="vt-t">DEC. 20, 2021</td> <td>(Reported) FY2021 incentive payment plan report</td> <td class="fc_black">-</td> <td rowspan="4" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Amendment to operational regulations of Related Party Transaction Committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="4" class="vt-t">OCT. 26, 2021</td> <td>(Reported) FY2021 3rd quarter earnings report</td> <td class="fc_black">-</td> <td rowspan="4" class="vt-m ta-c">6/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of charitable contributions</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">JUL. 27, 2021</td> <td>(Reported) Legal service fee for management's litigation</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td rowspan="6" class="vt-t">JUL. 27, 2021</td> <td>(Reported) FY2021 half year earnings report</td> <td class="fc_black">-</td> <td rowspan="6" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Amendment to operational regulations of Audit Committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Amendment to instructions of internal accounting management</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Joining new technology investment association</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Issuance of Corporate bond</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Approval of 2021 charitable contributions</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="2" class="vt-t">APR. 28, 2021</td> <td>(Reported) FY2021 1st quarter earnings report</td> <td class="fc_black">-</td> <td rowspan="2" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Constitution of ESG Committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">MAR. 19, 2021</td> <td>(Reported) 2021 incentive compensation plan</td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) Assessment of internal accounting management system by CEO and the Audit committee</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) Assessment of 2020 compliance review</td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Approval of 2021 compensation limit for Directiors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transaction with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">MAR. 19, 2021</td> <td><span class="indent_num">1. Approval of payment of legal services fee for management's litigation</span></td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/7</td> </tr> <tr> <td rowspan="9" class="vt-t">FEB. 26, 2021</td> <td>(Reported) Operation status of internal accounting management system</td> <td class="fc_black">-</td> <td rowspan="9" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) Evaluation and audit report of internal accounting management system</td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Payment of Samsung CI License</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Transaction of Golf Club membership with an affiliate company</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Amendment to operational regulations of Remuneration Committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Approval of establishment of operation of ESG committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Decision to convene the 10th(FY2020) AGM</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">6. Adoption of electronic voting system</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">7. Approval of 2021 Safety and Health management system</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="2" class="vt-t">FEB. 26, 2021</td> <td><span class="indent_num">1. Change of limit on legal services fee for management's litigation</span></td> <td class="fc_black">Approved</td> <td rowspan="2" class="vt-m ta-c">5/7</td> </tr> <tr> <td><span class="indent_num">2. Approval of change of members of Management Committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="3" class="vt-t">JAN. 26, 2021</td> <td><span class="indent_num">1. Approval of FY2020 financial statements and annual business report</span></td> <td class="fc_black">Approved</td> <td rowspan="3" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">2. Approval of operational improvement strategies of Remuneration Committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of concurrent positions of the Chief Executive Officer</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">JAN. 26, 2021</td> <td>1. Approval of payment of legal services fee for management's litigation</td> <td class="fc_black">Approved</td> <td class="vt-m ta-c">5/7</td> </tr> </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>DEC. 20, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 20, 2021 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2021 incentive payment plan report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Amendment to operational regulations of Related Party Transaction Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 26, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 26, 2021 <span class="unit">Attendance 6/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2021 3rd quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of charitable contributions</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 27, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 27, 2021 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Legal service fee for management's litigation</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 27, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 27, 2021 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2021 half year earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Amendment to operational regulations of Audit Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Amendment to instructions of internal accounting management</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Joining new technology investment association</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Issuance of Corporate bond</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Approval of 2021 charitable contributions</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>APR. 28, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">APR. 28, 2021 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2021 1st quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Constitution of ESG Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 19, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 19, 2021 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 2021 incentive compensation plan</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Assessment of internal accounting management system by CEO and the Audit committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Assessment of 2020 compliance review</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of 2021 compensation limit for Directiors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transaction with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 19, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 19, 2021 <span class="unit">Attendance 5/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of payment of legal services fee for management's litigation</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 26, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 26, 2021 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Operation status of internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Evaluation and audit report of internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Payment of Samsung CI License</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Transaction of Golf Club membership with an affiliate company</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Amendment to operational regulations of Remuneration Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Approval of establishment of operation of ESG committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Decision to convene the 10th(FY2020) AGM</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>6. Adoption of electronic voting system</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>7. Approval of 2021 Safety and Health management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 26, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 26, 2021 <span class="unit">Attendance 5/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Change of limit on legal services fee for management's litigation</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of change of members of Management Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 26, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 26, 2021 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2020 financial statements and annual business report</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of operational improvement strategies of Remuneration Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of concurrent positions of the Chief Executive Officer</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 26, 2021 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 26, 2021 <span class="unit">Attendance 5/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of payment of legal services fee for management's litigation</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2020</h4> <div class="pc block"> <table class="col_table"> <caption>2020 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="3" class="vt-t">DEC. 29, 2020</td> <td>(Reported) Report on operational improvement strategies of Remuneration Committee</td> <td class="fc_black">-</td> <td rowspan="3" class="vt-m ta-c">5/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of legal fee payment for a lawsuit against management</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Amendment to operational regulations of the Board of Directors (Introduction and operation of support staffs)</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="8" class="vt-t">DEC. 16, 2020</td> <td>(Reported) FY2021 business plan report</td> <td class="fc_black">-</td> <td rowspan="8" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) FY2020 incentive payment plan report</td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Joining a financial instrument of Samsung Securities</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Payment of retirement pension</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Charitable contributions</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">6. Appointment of Chief Executive Officer</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">OCT. 21, 2020</td> <td>(Reported) FY2020 3rd quarter earnings report</td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">7/7</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Amendment to operational regulations and instructions of internal accounting management</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Appointment of compliance manager</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">SEP. 25, 2020</td> <td><span class="indent_num">(Reported) Report on progress regarding prosecution of executive</span></td> <td class="fc_black">-</td> <td class="vt-m ta-c">7/7</td> </tr> <tr> <td class="vt-t">AUG. 11, 2020</td> <td><span class="indent_num">1. Approval of investment in Plant 4</span></td> <td class="fc_black">Approved</td> <td class="vt-m ta-c">7/7</td> </tr> <tr> <td rowspan="6" class="vt-t">JUL. 21, 2020</td> <td>(Reported) FY2020 half year earnings report</td> <td class="fc_black">-</td> <td rowspan="6" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) FY2020 1H company's evaluation result</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) Report on management issue</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) 2020 July executive appointment</td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholder (Samsung Electronics)</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Joining a financial instrument of Samsung Securities</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">APR. 20, 2020</td> <td>(Reported) FY2020 1st quarter earnings report</td> <td class="fc_black">-</td> <td class="vt-m ta-c">7/7</td> </tr> <tr> <td rowspan="7" class="vt-t">MAR. 20, 2020</td> <td>(Reported) 2020 incentive payment report</td> <td class="fc_black">-</td> <td rowspan="7" class="vt-m ta-c">7/7</td> </tr> <tr> <td>(Reported) Report of new facility investment</td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Appointment of CEO & director</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Appointment of Chairman of BOD</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Appointment of members of committees within the BOD</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Setting the remuneration of directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Approval of large-scale internal transactions</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">FEB. 28, 2020</td> <td>(Reported) Reporting the operation status of internal accounting management system</td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">5/5</td> </tr> <tr> <td>(Reported) Evaluation and audit report of the internal accounting management system</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) Evaluation and report of compliance</td> <td class="fc_black">-</td> </tr> <tr> <td>(Reported) Report of major facility supplementary investment</td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Decision to convene the 9th (FY2019) AGM</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">JAN. 22, 2020</td> <td>1. Approval of FY2019 financial statements and annual business report</td> <td class="fc_black">Approved</td> <td class="ta-c">5/5</td> </tr> <tr> <td class="vt-t">JAN. 10, 2020</td> <td>1. Approval of the establishment of a foreign corporation in the U.S.</td> <td class="fc_black">Approved</td> <td class="ta-c">5/5</td> </tr>  </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>DEC. 29, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 29, 2020 <span class="unit">Attendance 5/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Report on operational improvement strategies of Remuneration Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of legal fee payment for a lawsuit against management</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Amendment to operational regulations of the Board of Directors (Introduction and operation of support staffs)</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>DEC. 16, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 16, 2020 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2021 business plan report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2020 incentive payment plan report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Joining a financial instrument of Samsung Securities</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Payment of retirement pension</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Charitable contributions</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>6. Appointment of Chief Executive Officer</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 21, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 21, 2020 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2020 3rd quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Amendment to operational regulations and instructions of internal accounting management</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Appointment of compliance manager</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>SEP. 25, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">SEP. 25, 2020 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Report on progress regarding prosecution of executive</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>AUG. 11, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">AUG. 11, 2020 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of investment in Plant 4</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 21, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 21, 2020 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2020 half year earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2020 1H company's evaluation result</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Report on management issue</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 2020 July executive appointment</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholder (Samsung Electronics)</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Joining a financial instrument of Samsung Securities</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>APR. 20, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">APR. 20, 2020 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2020 1st quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 20, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 20, 2020 <span class="unit">Attendance 7/7</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) 2020 incentive payment report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Report of new facility investment</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Appointment of CEO & director</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Appointment of Chairman of BOD</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Appointment of members of committees within the BOD</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Setting the remuneration of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Approval of large-scale internal transactions</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 28, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 28, 2020 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Reporting the operation status of internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Evaluation and audit report of the internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Evaluation and report of compliance</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Report of major facility supplementary investment</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Decision to convene the 9th (FY2019) AGM</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 22, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 22, 2020 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2019 financial statements and annual business report</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 11, 2020 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 11, 2020 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of the establishment of a foreign corporation in the U.S.</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2019</h4> <div class="pc block"> <table class="col_table"> <caption>2019 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="5" class="vt-t">DEC. 16, 2019</td> <td>(Reported) FY2019 Incentive payment status</td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholder</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Joining a financial instrument of Samsung Securities</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Payment of retirement pension</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">OCT. 23, 2019</td> <td>(Reported) FY2019 3Q earnings report</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td class="vt-t">SEP. 11, 2019</td> <td>(Reported) Discussions on the creation of a support organization in the Audit Committee</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td rowspan="2" class="vt-t">JUL. 23, 2019</td> <td>(Reported) FY2019 half year earnings report </td> <td class="fc_black">-</td> <td rowspan="2" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Approval of FY2018 financial statements corrections</span></td> <td class="fc_black">-</td> </tr> <tr> <td rowspan="2" class="vt-t">APR. 24, 2019</td> <td><span class="indent_num">(Reported) FY2019 1st quarter earnings report</span></td> <td class="fc_black">-</td> <td rowspan="2" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="4" class="vt-t">MAR. 22, 2019</td> <td><span class="indent_num">1. Appointment of members of committees within the BOD</span></td> <td class="fc_black">Approved</td> <td rowspan="4" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Setting the remuneration of directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Joining a financial instrument of Samsung Securities</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">FEB. 27, 2019</td> <td><span class="indent_num">(Report) Reporting the operation status of internal accounting management system</span></td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">(Report) Evaluation and audit report of the internal accounting management system</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">(Report) 2019 Incentive Payment Report</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">(Report) Evaluation and report of 2018 Compliance</span></td> <td class="fc_black">-</td> </tr> <tr> <td><span class="indent_num">1. Decision to convene the 8th(FY2018) AGM</span></td> <td class="fc_black">-</td> </tr> <tr> <td rowspan="5" class="vt-t">JAN. 31, 2019</td> <td><span class="indent_num">1. Approval of FY2018 financial statements and annual business report</span></td> <td class="fc_black">-</td> <td rowspan="5" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Approval of revision of the operation regulations of audit committee</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of revision of internal accounting control system regulations</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Addition of New Business Place</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>DEC. 16, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 16, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2019 Incentive payment status</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholder</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Joining a financial instrument of Samsung Securities</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Payment of retirement pension</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 23, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 23, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2019 3Q earnings report</td> </tr> </tbody> </table> <table class="col_table"> <caption>SEP. 11, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">SEP. 11, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) Discussions on the creation of a support organization in the Audit Committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 23, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 23, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2019 half year earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2018 financial statements corrections</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>APR. 24, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">APR. 24, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported) FY2019 1st quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 22, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 22, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Appointment of members of committees within the BOD</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Setting the remuneration of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Joining a financial instrument of Samsung Securities</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 27, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 27, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Report) Reporting the operation status of internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Report) Evaluation and audit report of the internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Report) 2019 Incentive Payment Report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>(Report) Evaluation and report of 2018 Compliance</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Decision to convene the 8th(FY2018) AGM</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 31, 2019 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 31, 2019 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2018 financial statements and annual business report</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of revision of the operation regulations of audit committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of revision of internal accounting control system regulations</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Addition of New Business Place</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2018</h4> <div class="pc block"> <table class="col_table"> <caption>2018 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="4" class="vt-t">DEC. 24, 2018</td> <td>1. Approval of transactions with major shareholders</td> <td class="fc_black">Approved</td> <td rowspan="4" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Payment of retirement pension</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Revision of the in-house trade committee’s operation provisions</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="3" class="vt-t">OCT. 23, 2018</td> <td>(Reported Item) FY2018 3rd quarter earnings report</td> <td class="fc_black">-</td> <td rowspan="3" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Time deposits of Samsung Securities Co., Ltd.</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Investments in subsidiaries</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">OCT. 04, 2018</td> <td>(Reported Item) Report on Major Management Issues</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td class="vt-t">JUL. 23, 2018</td> <td>(Reported Item) FY2018 1st half year earnings report</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td class="vt-t">JUN. 28, 2018</td> <td><span class="indent_num">(Reported Item) Report on Major Management Issues</span></td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td rowspan="3" class="vt-t">APR. 24, 2018</td> <td><span class="indent_num">(Reported Item) FY2018 1st quarter earnings report</span></td> <td class="fc_black">-</td> <td rowspan="3" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Issue of Corporate bond</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Approval of trading with controlling shareholder</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">MAR. 22, 2018</td> <td><span class="indent_num">1. Setting the remuneration of directors</span></td> <td class="fc_black">Approved</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td rowspan="3" class="vt-t">FEB. 28, 2018</td> <td><span class="indent_num">(Reported Item) Report on the internal accounting management system</span></td> <td class="fc_black">-</td> <td rowspan="3" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Approval of FY2017 financial statements and annual business report</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Decision to convene the 7th(FY2017) AGM</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="3" class="vt-t">JAN. 31, 2018</td> <td><span class="indent_num">(Reported Item) Performance bonus of FY2017 for key objectives</span></td> <td class="fc_black">-</td> <td rowspan="3" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Approval of FY2017 financial statements and annual business report</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">2. Revision of the operation regulations of the independent director referral committee</span></td> <td class="fc_black">Approved</td> </tr> </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>DEC. 24, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 24, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Payment of retirement pension</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Revision of the in-house trade committee’s operation provisions</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 23, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 23, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported Item) FY2018 3rd quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Time deposits of Samsung Securities Co., Ltd.</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Investments in subsidiaries</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>OCT. 04, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">OCT. 04, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported Item) Report on Major Management Issues</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 23, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 23, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported Item) FY2018 1st half year earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUN. 28, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 28, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported Item) Report on Major Management Issues</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>APR. 24, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">APR. 24, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported Item) FY2018 1st quarter earnings report</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Issue of Corporate bond</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of trading with controlling shareholder</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 22, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 22, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Setting the remuneration of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 28, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 28, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported Item) Report on the internal accounting management system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2017 financial statements and annual business report</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Decision to convene the 7th(FY2017) AGM</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 31, 2018 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 31, 2018 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>(Reported Item) Performance bonus of FY2017 for key objectives</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of FY2017 financial statements and annual business report</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Revision of the operation regulations of the independent director referral committee</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2017</h4> <div class="pc block"> <table class="col_table"> <caption>2017 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="2" class="vt-t">JUL. 24, 2017</td> <td>Report on financial results concerning 2Q/2017</td> <td class="fc_black">-</td> <td rowspan="2" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">JUL. 30, 2017</td> <td>Report on result of corporate appraisal of the company in the first half of 2017</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td rowspan="2" class="vt-t">MAY. 18, 2017</td> <td>Report on status of operation of the company’s evaluation/remuneration system</td> <td class="fc_black">-</td> <td rowspan="2" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">1. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">APR. 25, 2017</td> <td>Report on financial results concerning 1Q/2017</td> <td class="fc_black">-</td> <td class="vt-m ta-c">5/5</td> </tr> <tr> <td rowspan="5" class="vt-t">MAR. 24, 2017</td> <td><span class="indent_num">1. Election of the representative director and entrustment of business to directors</span></td> <td class="fc_black">Approved</td> <td rowspan="5" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Appointment of the chairperson of the board of directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Appointment of members of the committees of the board of directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Execution of limit of directors’ remuneration</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Revision of the rules and regulations of the board of directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="2" class="vt-t">FEB. 27, 2017</td> <td><span class="indent_num">1. Convening of the general meeting of shareholders and decision on purpose of the meeting</span></td> <td class="fc_black">Approved</td> <td rowspan="2" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td class="vt-t">JAN. 24, 2017</td> <td><span class="indent_num">1. Convening of the general meeting of shareholders and decision on purpose of the meeting</span></td> <td class="fc_black">Approved</td> <td class="vt-m ta-c">5/5</td> </tr> </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>JUL. 24, 2017 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 24, 2017 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>Report on financial results concerning 2Q/2017</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JUL. 30, 2017 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JUL. 30, 2017 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>Report on result of corporate appraisal of the company in the first half of 2017</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAY. 18, 2017 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAY. 18, 2017 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>Report on status of operation of the company’s evaluation/remuneration system</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>1. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>APR. 25, 2017 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">APR. 25, 2017 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>Report on financial results concerning 1Q/2017</td> </tr> <tr> <th class="fc_black">Result</th> <td>-</td> </tr> </tbody> </table> <table class="col_table"> <caption>MAR. 24, 2017 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">MAR. 24, 2017 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Election of the representative director and entrustment of business to directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Appointment of the chairperson of the board of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Appointment of members of the committees of the board of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Execution of limit of directors’ remuneration</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Revision of the rules and regulations of the board of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>FEB. 27, 2017 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">FEB. 27, 2017 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Convening of the general meeting of shareholders and decision on purpose of the meeting</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>JAN. 24, 2017 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">JAN. 24, 2017 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Convening of the general meeting of shareholders and decision on purpose of the meeting</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> <div class="border_wrap"> <h4 class="border_tit t_uppercase">2016</h4> <div class="pc block"> <table class="col_table"> <caption>2016 Activity of the BOD - Date, Agenda, Result, Attendance</caption> <colgroup> <col style="width:17%;"> <col> <col style="width:14%;"> <col style="width:15%;"> </colgroup> <thead> <tr> <th scope="col" class="fc_gray_666">Date</th> <th scope="col" class="fc_gray_666">Agenda</th> <th scope="col" class="fc_gray_666">Result</th> <th scope="col" class="fc_gray_666 ta-c">Attendance</th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <td rowspan="5" class="vt-t">DEC. 13, 2016</td> <td><span class="indent_num">1. Participation in Samsung Bioepis’ capital increase</span></td> <td class="fc_black">Approved</td> <td rowspan="5" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Participation in Archigen’s capital increase</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Approval of transactions with major shareholders</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Approval of transactions with specially related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Subscription to retirement pension</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="2" class="vt-t">SEP. 29, 2016</td> <td><span class="indent_num">1. Approval for issuance of new shares for IPO and for sales of old shares</span></td> <td class="fc_black">Approved</td> <td rowspan="2" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Approval of internal trading with specially related parties</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td rowspan="5" class="vt-t">AUG. 10, 2016</td> <td><span class="indent_num">1. Appointment of the chairperson of the board of directors</span></td> <td class="fc_black">Approved</td> <td rowspan="5" class="vt-m ta-c">5/5</td> </tr> <tr> <td><span class="indent_num">2. Entrusting business to directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">3. Appointment of the members of the committees of the board of directors</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">4. Appointment of the compliance officer</span></td> <td class="fc_black">Approved</td> </tr> <tr> <td><span class="indent_num">5. Appointment of the transfer agent</span></td> <td class="fc_black">Approved</td> </tr> </tbody> </table> </div> <div class="mobile block"> <table class="col_table"> <caption>DEC. 13, 2016 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">DEC. 13, 2016 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Participation in Samsung Bioepis’ capital increase</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Participation in Archigen’s capital increase</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Approval of transactions with major shareholders</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Approval of transactions with specially related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Subscription to retirement pension</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>SEP. 29, 2016 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">SEP. 29, 2016 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Approval for issuance of new shares for IPO and for sales of old shares</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Approval of internal trading with specially related parties</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> <table class="col_table"> <caption>AUG. 10, 2016 Activity of the BOD - Date, Attendance, Agenda, Result, </caption> <colgroup> <col style="width:36%;"> <col> </colgroup> <thead> <tr> <th scope="col" colspan="2" class="fc_gray_666"> <div class="relative">AUG. 10, 2016 <span class="unit">Attendance 5/5</span></div> </th> </tr> </thead> <tbody class="fc_gray_666"> <tr> <th class="fc_black">Agenda</th> <td>1. Appointment of the chairperson of the board of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>2. Entrusting business to directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>3. Appointment of the members of the committees of the board of directors</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>4. Appointment of the compliance officer</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> <tr> <th class="fc_black">Agenda</th> <td>5. Appointment of the transfer agent</td> </tr> <tr> <th class="fc_black">Result</th> <td>Approved</td> </tr> </tbody> </table> </div> </div> </div> </div> </div> </div>  <div id="footer"> <div class="footer_cont"> <div class="footer_layer v231027"> <div class="pix-in"> <div class="flex-box typ2 "> <div class="conts"> <h4>Cookies</h4> <p> We use cookies to improve the experience for visitors to our websites including site operation, analytics, or advertising. Choose the use of cookies and/or modify your preferences <a href="#" class="cookiePolicy" title="Layer Popup Open">here.</a> </p> </div> <div class="btns"> <a href="#" class="btnLink"><span>Accept cookies</span></a> <a href="#" class="btnLink2"><span>Reject cookies</span></a> </div> </div>  </div> </div> <div class="footer_cont_bottom btns-line"> <ul class="footer_link"> <li><a href="#" class="siteMap" title="Layer Popup Open">Site Map</a></li>  <li><a href="/privacy-policy" class="privatePolicy">Privacy Policy</a></li> <li><a href="#" class="cookiePolicy" title="Layer Popup Open">Cookie Policy</a></li> <li><a href="https://audit.samsungbiologics.com:7151/gcc/portal/main.do?lang=en_US" target="_blank" title="window open">Business Ethics</a></li>  <li><a href="/security-report" title="Security Report">Security Report</a></li> <li><a href="https://sblself.v-pass.net:8096" target="_blank" title="window open">Visit Request</a></li> </ul> <ul class="footer_sns">  <li class="ml0"><a href="https://www.linkedin.com/company/samsung-biologics/" class="linkedin" target="_blank" title="Window Open">linkedin</a></li> <li><a href="https://www.instagram.com/samsung_biologics/" class="instagram" target="_blank" title="Window Open">instagram</a></li> <li><a href="https://www.facebook.com/samsungbiologics" class="facebook" target="_blank" title="Window Open">facebook</a></li> <li><a href="https://www.youtube.com/channel/UCTaOU9vqcFgVl0Spiw-pwTQ/videos" class="youtube" target="_blank" title="Window Open">youtube</a></li> </ul> </div> <div class="footer_info"> <div class="footer_cont_bottom"> <p class="address v231205"> 300, Songdo bio-daero, Yeonsu-gu, Incheon, Republic of Korea <a href="https://www.google.com/maps/search/Samsung+Biologics/data=!3m1!4b1?entry=ttu" target="_blank" title="window open">Directions</a> </p> <p class="copyright">Copyright ⓒ 2025 Samsung Biologics. All rights reserved.</p> <div class="footer_evaluation"> <ul> <li><span class="ffm"><span class="hidden">Best Family-Friendly Management Mark</span></span></li> <li><span class="web_accessibility"><span class="hidden">Ministry of Science and ICT WA (Web Accessibility)Quality Certification Mark</span></span></li> <li><span class="korea_aeo"><span class="hidden">KOREA AEO Mark</span></span></li> </ul> </div> </div> </div> </div> </div>  <div class="site_map"> <div class="site_map_top pix-in"> <h2>SITE MAP</h2> <a href="#" class="close">close</a> </div> <div class="site_map_cont pix-in"> <ul> <li> <a href="/about/our-dna">ABOUT US</a> <ul> <li> <a href="/about/our-dna">Company</a> <ul> <li><a href="/about/our-dna">Our DNA</a></li> <li><a href="/about/samsungbiologics-way">Samsung Biologics Way</a></li> <li><a href="/about/fact-sheet">Fact Sheet</a></li> <li><a href="/about/milestones">Milestones</a></li> </ul> </li>  <li> <a href="/about/leadership/key-executives">Leadership</a> <ul> <li><a href="/about/leadership/key-executives">Key Executives</a></li> <li><a href="/about/leadership/ceo">CEO Message</a></li> </ul> </li> <li> <a href="/about/headquarters">Location</a> <ul> <li> <a href="/about/headquarters">Headquarters</a> <ul> <li><a href="/about/bio-campus1">Bio Campus I</a></li> <li><a href="/about/bio-campus2">Bio Campus II : Plant 5</a></li> </ul> </li> <li><a href="/about/sba">Samsung Biologics America</a></li> </ul> </li> </ul> </li> <li> <a href="/services/biopharma-development">OUR SERVICES</a> <ul> <li> <a href="/services/biopharma-development">Development Services</a> <ul> <li class="mobile"><a href="/services/biopharma-development">Overview</a></li> <li><a href="/services/cdo/discovery">Late Discovery</a></li> <li><a href="/services/cdo/cell-line-development">Cell Line Development</a></li> <li><a href="/services/cdo/process-development">Process Development</a></li> <li><a href="/services/cdo/analytical-development">Analytical Development</a></li>  <li><a href="/services/cdo/manufacturing">Non-GMP / CGMP Manufacturing</a></li> </ul> </li> </ul> <ul> <li> <a href="/services/biopharma-manufacturing">Manufacturing Services</a> <ul> <li class="mobile"><a href="/services/biopharma-manufacturing">Overview</a></li> <li> <a href="/services/cmo/mammalian-cell-culture">Drug Substance</a>  </li> <li><a href="/services/cmo/drug-product">Drug Product</a></li> </ul> </li> </ul> <ul> <li> <a href="/services/biopharma-quality">Quality Services</a> <ul> <li class="mobile"><a href="/services/biopharma-quality">Overview</a></li> <li><a href="/services/quality/quality-assurance">Quality Assurance</a></li> <li><a href="/services/quality/quality-control">Quality Control</a></li>  <li><a href="/services/quality/analytical-testing-services">Analytical Testing Services</a></li> </ul> </li> </ul> <ul> <li> <a href="/services/adc">New Modalities</a> <ul> <li><a href="/services/adc">Antibody-Drug Conjugates</a></li> <li><a href="/services/newmodalities/mRNA">mRNA</a></li>  </ul> </li> </ul> </li> <li> <a href="/careers/value">CAREERS</a> <ul> <li><a href="/careers/value">Our Values</a></li> <li> <a href="/careers/working-with-us/career-development">Working With Us</a> <ul> <li><a href="/careers/working-with-us/career-development">Career Development</a></li> <li><a href="/careers/working-with-us/benefits">Benefits</a></li> <li><a href="/careers/working-with-us/diversity-inclusion">Diversity & Inclusion</a></li> </ul> </li> <li> <a href="/careers/apply/how-to-apply">How to Apply</a> <ul> <li><a href="/careers/apply/how-to-apply">Application Process</a></li> <li><a href="/careers/apply/faqs">FAQs</a></li> </ul> </li>  <li><a href="/careers/recruitment-support/step1"><span>Job Information</span></a></li> </ul> </li> </ul> <ul> <li> <a href="/esg/our-commitment">SUSTAINABILITY</a> <ul> <li> <a href="/esg/our-commitment">ESG Management</a> <ul> <li><a href="/esg/our-commitment"><span>Our Commitment</span></a></li> <li><a href="/esg/resources"><span>Resources</span></a></li> </ul> </li> <li> <a href="/esg/environment/climate-actions">Environmental</a> <ul> <li><a href="/esg/environment/climate-actions"><span>Climate Actions</span></a></li> <li><a href="/esg/environment/she"><span>SHE Management</span></a></li> <li><a href="/esg/environment/environment"><span>Environment</span></a></li> <li><a href="/esg/environment/safety"><span>Safety</span></a></li> <li><a href="/esg/environment/health"><span>Health</span></a></li> </ul> </li> <li> <a href="/esg/social/human-rights">Social</a> <ul> <li><a href="/esg/social/human-rights"><span>Human Rights</span></a></li> <li><a href="/esg/social/compliance"><span>Compliance</span></a></li> <li><a href="/esg/social/ethics"><span>Business Ethics</span></a></li> <li><a href="/esg/social/csr"><span>Corporate Social Responsibility</span></a></li> <li><a href="/esg/social/suppliers"><span>Suppliers</span></a></li> <li><a href="/esg/social/bcms"><span>BCMS</span></a></li> </ul> </li> <li> <a href="/esg/governance/articles">Governance</a> <ul class="depth3"> <li><a href="/esg/governance/articles">Articles of Incorporation</a></li> <li><a href="/esg/governance/board-structure">Board Structure</a></li> <li><a href="/esg/governance/bod-committees">BOD Committees</a></li> <li><a href="/esg/governance/corporate-governance-report">Corporate Governance</a></li> <li><a href="/esg/governance/exAuditList">External Auditor</a></li> </ul> </li> </ul> </li> <li> <a href="/ir/overview">INVESTORS</a> <ul> <li> <a href="/ir/overview">Overview</a> </li> <li> <a href="/ir/financial-info/financial-snapshot">Financial Information</a> <ul class="depth3"> <li><a href="/ir/financial-info/financial-snapshot">Financial Snapshot</a></li> <li> <a href="/ir/financial-info/financial-statements">Financial Report</a> <ul> <li><a href="/ir/financial-info/financial-statements">Financial Statements </a></li> <li><a href="/ir/financial-info/annual-business-report">Business Report</a></li> <li><a href="/ir/financial-info/earning-release">Earnings Release</a></li> </ul> </li> </ul> </li> <li> <a href="/ir/stock-info/listing-information">Stock & Shareholder<br class="pc"> Information</a> <ul class="depth3"> <li><a href="/ir/stock-info/listing-information">Listing Information</a></li> <li><a href="/ir/stock-info/stock-charts">Stock Charts</a></li> <li><a href="/ir/stock-info/ownership-structure">Ownership Structure</a></li> <li><a href="/ir/stock-info/general-meeting">General Meeting of Shareholders</a></li> </ul> </li>  <li> <a href="/ir/resource/notice">IR Resource</a> <ul class="depth3"> <li><a href="http://engkind.krx.co.kr/disclosure/searchdisclosurebycorp.do?method=searchDisclosureByCorpMain&searchCodeType=char&searchCorpName=Samsung%20biologics" target="_blank" title="window open">Public Disclosures</a></li> <li><a href="/ir/resource/notice">IR Notice</a></li>  </ul> </li> </ul> </li> <li> <a href="/media/newsroom">NEWSROOM</a> <ul> <li> <a href="/media/newsroom">Newsroom</a> </li> <li> <a href="/media/company-news">Company News</a> <ul> <li><a href="/media/company-news?schBoardCtgryCcd=1">Press Release</a></li> <li><a href="/media/company-news?schBoardCtgryCcd=6">News Brief</a></li> <li><a href="/media/company-news?schBoardCtgryCcd=7">Media Focus</a></li> </ul> </li> <li> <a href="/media/bio-story">Our Story</a> <ul> <li><a href="/media/bio-story?schBoardCtgryCcd=1">Life @ Samsung Biologics</a></li> <li><a href="/media/bio-story?schBoardCtgryCcd=3">Samsung Bio Insight</a></li> </ul> </li> <li> <a href="/media/science-technology">Science & Technology</a> <ul> <li><a href="/media/science-technology?schBoardCtgryCcd=1">Whitepapers</a></li> <li><a href="/media/science-technology?schBoardCtgryCcd=2">Posters</a></li> <li><a href="/media/science-technology?schBoardCtgryCcd=3">Webinars</a></li> </ul> </li> <li> <a href="/media/pr-materials">PR Materials</a> <ul> <li><a href="/media/pr-materials?tab=1">Brochures & Infographics</a></li> <li><a href="/media/pr-materials?tab=2">Company Images</a></li> <li><a href="/media/pr-materials?tab=3"><span>Videos</span></a></li> </ul> </li> <li><a href="/media/events">Events</a></li>  </ul> </li> </ul> <ul> <li> <a href="/contact-us" class="last">CONTACT US</a> </li> </ul> </div> </div>   <div class="layer_downLoad">  <div class="fileDownBody setDown"> <a href="#" class="close">Close</a> <h3>Your download is ready</h3> <p class="txt">Click Download.</p> <div class="btns"> <a href="#" class="last" id="btnDownload" title="Download">Download</a> </div> </div>      <div class="fileDownBody setNewsLetterWrite"> <a href="#" class="close">Close</a> <div class="news-letter miniScroll"> <h3>Subscribe to Our Newsletter</h3> <p class="txt"> Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter. </p> <form id="frm_subscribe" name="frm_subscribe" method="post" action="#" > <input type="hidden" id="lang" name="lang" value=""> <input type="hidden" id="scodelist" name="scodelist"> <fieldset> <legend>Subscribe to Our Newsletter</legend> <ul class="field-list"> <li> <dl> <dt><label for="layerFromEmail">E-mail</label></dt> <dd><input type="text" id="layerFromEmail" name="layerFromEmail"></dd> </dl> </li> <li> <dl> <dt><label for="layerSubscribeCompany">Company</label></dt> <dd><input type="text" id="layerSubscribeCompany" name="layerSubscribeCompany"></dd> </dl> </li> <li> <dl> <dt><label for="layerSubscribeName">Name</label></dt> <dd><input type="text" id="layerSubscribeName" name="layerSubscribeName"></dd> </dl> </li> <li> <dl> <dt><label for="layerSubscribeJobtitle">Job Title</label></dt> <dd><input type="text" id="layerSubscribeJobtitle" name="layerSubscribeJobtitle"></dd> </dl> </li> <li> <dl> <dt><label for="user-country">Country</label></dt> <dd> <select name="user-country" id="user-country" class="countryList"> <option>Search Country</option> </select> </dd> </dl> </li> <li class="space-typ1"> <dl> <dt><span class="tit">Interests</span></dt>  <dd> <ul class="checkbox-list" id="interestListUl"> <li> <span class="checkbox"> <input type="checkbox" id="user-all"> <label for="user-all">All</label> </span> </li> </ul> </dd> </dl> </li> <li class="space-typ2"> <div class="policy"> <span class="checkbox"> <input type="checkbox" id="layerPolicy"> <label for="layerPolicy"> I agree to the </label> <a href="/privacy-policy" target="_blank" title="Window Open">Privacy Policy</a> to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers. </span> </div> </li> </ul> <div class="btn-submit"> <input type="submit" value="SUBSCRIBE" id="btn_subscribe" class="last" /> </div> </fieldset> </form> </div> </div>   <div class="fileDownBody setPleaseSignWrite"> <a href="#" class="close">Close</a> <div class="news-letter miniScroll"> <h3> Please fill out the form<br /> to view the full content </h3>  <script src="https://www.linkedin.com/autofill/js/autofill.js" type="text/javascript" async></script>    <script> $(document).ready(function () { locationList(); //$("#selectBox option").each(function(){ console.log( $(this).val() ); }) var signupUsercountries = $('#signupUser-country-select'); var signupUserautofilledCountry = $('#signuplocationAutofill'); var signuptempcloneInit = $(".countryList option").clone(); var signuptempclone = signuptempcloneInit.clone(); var signupTimer = window.setInterval(function () { if ( '' == signupUserautofilledCountry.val() ) { return; } signupUsercountries .find('option[value='+signupUserautofilledCountry.val()+']') .attr('selected', 'selected'); var countriesData = signupUsercountries .find('option[value='+signupUserautofilledCountry.val()+']') .data('value'); $('#signupUser-country').val(countriesData); clearInterval(signupTimer); }, 500); $("#signupUser-country-select").on("change", function(){ console.log($("#signupUser-country-select option:selected").data('value')); $('#signupUser-country').val($("#signupUser-country-select option:selected").data('value')); }); }); </script> <form id="frm_sign_up" name="frm_sign_up" method="post" > <input type="hidden" id="formAttachmentOrgFileNm" name="formAttachmentOrgFileNm"> <input type="hidden" id="formAttachmentPhgsFileNm" name="formAttachmentPhgsFileNm"> <input type="hidden" id="formSub" name="formSub"> <input type="hidden" id="formLink" name="formLink"> <input type="hidden" id="boardsourcenm" name="boardsourcenm"> <fieldset> <legend>Please sign up to view the post..</legend> <ul class="field-list last-line"> <li> <dl> <dt><label for="signupUserFirstName"><span>First name</span></label></dt> <dd><input type="text" id="signupUserFirstName" name="signupUserFirstName"></dd> </dl> </li> <li> <dl> <dt><label for="signupUserLastName"><span>Last name</span></label></dt> <dd><input type="text" id="signupUserLastName" name="signupUserLastName"></dd> </dl> </li> <li> <dl> <dt><label for="signupLayerFromEmail"><span>E-mail</span></label></dt> <dd><input type="text" id="signupLayerFromEmail" name="signupLayerFromEmail"></dd> </dl> </li> <li> <dl> <dt><label for="signuplayerCompany"><span>Company</span></label></dt> <dd><input type="text" id="signuplayerCompany" name="signuplayerCompany"></dd> </dl> </li> <li> <dl> <dt><label for="signuplayerCompanyType"><span>Company Type</span></label></dt> <dd> <select name="signuplayerCompanyType" id="signuplayerCompanyType"> <option value="" >Search Company Type</option> <option value="Bio/Pharmaceutical company" data-attr="Bio/Pharmaceutical company" >Bio/Pharmaceutical company</option> <option value="Educational institution" data-attr="Educational institution" >Educational institution</option> <option value="Investment firm" data-attr="Investment firm" >Investment firm</option> <option value="Others" data-attr="Others" >Others</option> </select> </dd> </dl> </li> <li> <dl> <dt><label for="signuplayerJobtitle"><span>Job title</span></label></dt> <dd><input type="text" id="signuplayerJobtitle" name="signuplayerJobtitle"></dd> </dl> </li> <li> <dl> <dt><label for="signupUserDepartment" class="no-required"><span>Department</span></label></dt> <dd><input type="text" id="signupUserDepartment" name="signupUserDepartment"></dd> </dl> </li> <li> <dl> <dt><label for="signupUser-country-select" class="no-required"><span>Country</span></label></dt> <dd> <select name="signupUser-country-select" id="signupUser-country-select" class="countryList"> <option>Search Country</option> </select>  <input type="hidden" id="signuplocationAutofill" name="signuplocationAutofill" class="hidden" /> <input type="hidden" id="signupUser-country" name="signupUser-country" class="hidden" /> </dd> </dl> </li> </ul> <div class="required-txt"><span>*</span> Required</div>  <div class="terms tl"> <span class="checkbox"> <input type="checkbox" name="signupLayerPolicy" id="signupLayerPolicy" value="Y"> <label for="signupLayerPolicy">I agree to the </label> <a href="/privacy-policy" target="_blank" title="Window Open">Privacy Policy</a> <span class="ico-req">required</span> </span> </div> <div class="terms tl"> <span class="checkbox"> <input type="checkbox" id="signupMarkettingAgree" name="signupMarkettingAgree" value="Y"> <label for="signupMarkettingAgree">Join our community to receive the latest news, information, and tailored marketing resources. </label> </span> </div> <div class="btn-submit"> <input type="submit" value="View" id="btn_signup" class="last" /> </div> </fieldset> </form> </div> </div>  </div>   <div class="cookie_policy"> <div class="cookieBox"> <a href="#" class="close">close</a> <div class="policy_top"> <h2>COOKIE POLICY</h2> </div> <div class="policy_cont"> <a href="#" class="anchor">Get focus link</a> <div class="cont4"> <div class="cont_tit update"> <strong>Last Updated: [31 Mar 2023]</strong> </div> <p>This Cookie Policy applies to the Samsung Biologics website (the “Website”). Please read this Cookie Policy carefully and feel free to contact us if you have any questions.</p> </div> <div class="cont4 line"> <div class="cont_tit"> <strong>Your Privacy</strong> </div> <dl> <dt>- What are cookies?</dt> <dd> <p>A cookie is a small text file that a website saves on your computer or mobile device when you visit the Website. It enables the Website to remember your actions and preferences (such as language preferences) over a period of time, so you don't have to keep re-entering them whenever you come back to the Website or browse from one page to another.</p> </dd> </dl> <dl> <dt>- How to control cookies</dt> <dd> <p>You can control and/or delete cookies as you wish - for details, see http://www.aboutcookies.org. You can delete all cookies that are already on your computer and you can set most browsers to prevent them from being placed. If you do this, however, you may have to manually adjust some preferences every time you visit a site and some services and functionalities may not work.</p> </dd> </dl> </div> <div class="cont4 line"> <div class="cont_tit"> <strong>Strictly Necessary <br class="mobile block"/>Cookies</strong> <div class="always">Always Active</div> </div> <p> These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information. </p> </div> <div class="cont4 line"> <div class="cont_tit"> <strong>Performance <br class="mobile block"/>Cookies</strong> <div class="switch"> <label for="performance_cookie"> <input type="checkbox" id="performance_cookie" name="performance_cookie" /> <span class="button">Performance Cookies question of assent</span> </label> </div> </div> <p> These cookies are used to collect information about how visitors use our website. We use the information to compile reports and to help us improve the website. The cookies collect information in an anonymous form, including the number of visitors to the website, where visitors have come to the website from and the pages they visited. </p> <p><strong>Google Analytics</strong></p> <p> This website uses Google Analytics, a website analytics service provided by Google, Inc. (“Google”). Google Analytics uses cookies and the information generated by the cookie is usually transmitted to a Google server in the USA and stored there. </p> <p> You can prevent Google’s collection of the data generated by the cookie and related use of the website, including your IP address, as well as the processing of such data by Google by downloading and installing the browser plug-in available under the following link: <a href="http://tolls.google.com/dlpage/gaoptout">http://tolls.google.com/dlpage/gaoptout</a>. </p> </div> <div class="cont4 line"> <div class="cont_tit"> <strong>Targeting <br class="mobile block"/>Cookies</strong> <div class="switch"> <label for="targeting_cookie"> <input type="checkbox" id="targeting_cookie" name="targeting_cookie" disabled /> <span class="button">Targeting Cookies question of assent</span> </label> </div> </div> <p> These Cookies are used by advertising companies to inform and serve personalized ads more relevant to your interests. These Cookies also may facilitate sharing information with social networks or recording your interactions with particular ads. </p> <p class="italic">We currently do not use any cookies in this category</p> <div class="btnWrap between"> <button type="button" id="cookie_save_btn" name="cookie_save_btn" class="cookie_save_btn"> <span>Confirm My Choices</span> </button> <button type="button" id="cookie_all_btn" name="cookie_all_btn" class="cookie_all_btn last"> <span>Accept cookies</span> </button> </div> </div> </div> </div> </div>   <div class="security_report"> <div class="securityBox"> <a href="#" class="close">close</a> <div class="report_top"> <h2>SECURITY REPORT</h2> </div> <div class="report_cont"> <p> Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development. </p> <ul> <li>This page is created for reporting core technology and management information leakage.</li> <li>The reported contents as well as the identity of the reporter are strictly secured.</li> </ul> <div class="notification"> <strong>THE MANUAL FOR SECURITY NOTIFICATION</strong> <div class="box"> <div class="input_box"> <span>E-mail</span> <a href="mailto:sbl.infosec@samsung.com" class="last">sbl.infosec@samsung.com</a> </div> </div> </div> </div> </div> </div>    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-W86KR3Z" height="0" width="0" style="display:none;visibility:hidden" title="googletagmanager"></iframe></noscript>   <script async src="https://www.googletagmanager.com/gtag/js?id=G-FV0EVD0EW3"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-FV0EVD0EW3'); </script>  <script async src="https://www.googletagmanager.com/gtag/js?id=UA-131724845-1"></script> <script> if (!getCookie("useCookie")){ window['ga-disable-GA_MEASUREMENT_ID'] = true; console.log("gtag disableCookies"); }else{ console.log("gtag enable!"); } </script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-131724845-1'); </script>    <script src="/resources/front/en/js/bootstrap.min.js"></script>   <script type="text/javascript"> _linkedin_partner_id = "1600545"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(l) { if (!l){window.lintrk = function(a,b){window.lintrk.q.push([a,b])}; window.lintrk.q=[]} var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(window.lintrk); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1600545&fmt=gif" /> </noscript>  <script> $(function(){ $(".footer_layer .pix-in .bannerClose").on("click", function(){ $(".footer_layer").slideUp(300); // 접근성 심사때 필요함 //$(".footer_cont_bottom .footer_link li:first-child a:first-child").focus(); }); $(".footer_layer .pix-in .bannerClose").on("keydown", function(e){ if( e.keyCode == 9) { if(!e.shiftKey){ e.preventDefault(); $(".footer_layer .pix-in .bannerClose").trigger("click"); } } }); }); </script> </div>  <script type="text/javascript" src="/_Incapsula_Resource?SWJIYLWA=719d34d31c8e3a6e6fffd425f7e032f3&ns=2&cb=1053946528" async></script></body> </html>

CINXE.COM

Board Structure | Governance | ESG | Samsung Biologics | The Leading Global CDMO with End-to-End Services